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ABSTRACT

STRUCTURE BASED LIGAND DESIGN FOR MONOAMINE TRANSPORTERS
AND MITOGEN ACTIVATED KINASE 5

By
Sankar Manepalli
May 2012

Dissertation supervised by Jeffry D. Madura
Depression is a major psychological disorder that affects a person's mental and
physical abilities. The National Institute of Mental Health (NIMH) classified it as a
serious medical illness. It causes huge economic, as well as financial impact on the people,
and it is also becoming a major public health issue. Antidepressant drugs are prescribed to
mitigate the suffering caused by this disorder. Different generations of antidepressants
have been developed with dissimilar mechanisms of action. According to the Center for
Disease Control, the usage of antidepressants has skyrocketed by 400 percent increase
over 2005- 2008 survey period. This dramatic rise in usage indicates that these are the
most prescribed drugs in the US. Even with the FDA mandated “black box” warning of
increased suicidal thoughts upon use of selected antidepressants, these drugs are still being
used at a higher rate.
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All classes of antidepressants are plagued by side effects with mainly sexual
dysfunction common among them. To avoid the adverse effects, an emphasis is to
discover novel structural drug scaffolds that can be further developed as a new generation
of antidepressants. The importance of this research is to discover structurally novel
antidepressants by performing in silico virtual screening (VS) of chemical databases using
the serotonin transporter (SERT). In the absence of a SERT crystal structure, a homology
model was developed. The homology model was utilized to develop the first structurebased pharmacophore for the extracellular facing secondary ligand binding pocket. The
pharmacophore captured the necessary drug-SERT interaction pattern for SERT inhibitory
action. This pharmacophore was employed as one of the filters for VS of candidate
ligands. The ten compounds identified were purchased and tested pharmacologically. Out
of the ten hits, three structurally novel ligands were identified as lead compounds. Two of
these compounds exhibited selectivity towards SERT; the remaining lead compound was
selective towards the dopamine transporter and displayed cocaine inhibition. The two
SERT selective compounds will provide new opportunities in the development of novel
therapeutics to treat depression.
For dopamine transporter (DAT), the study was based on recently developed
structurally diverse photo probes. In an effort to better understand the binding profile
similarities among these different scaffolds, the photo probes were docked into DAT. The
finger print analysis of the interaction pattern of docked poses was performed to identify
the inhibitor-binding sites.
For mitogen activated protein kinase 5 (MEK5), given the lack of structural
information, a homology model of MEK5 was developed to guide the rational design of

v

inhibitors. Docking of known MEK5 inhibitors into the homology model was performed
to understand the inhibitory interaction profile. Several series of analogues were designed
utilizing the generated interaction profile.
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Chapter 1.
MONOAMINE TRANSPORTER STRUCTURE, FUNCTION
AND DRUG DISCOVERY: A COMPUTATIONAL REVIEW

1.1 Introduction
Monoamine transporters (MATs) are

important

proteins that

maintain

neurotransmitter homeostasis in brain synapses. The monoamine hypothesis shows that
dysfunction of these critical gatekeepers result in the imbalance of monoamine
neurotransmitters in the synapse, linked to various disease states such as depression,
addiction and other major neurological disorders. 1-6

The control of several body

functions such as hunger, sleep and mood is maintained by neurotransmitter homeostasis.
A critical understanding of MATs will help design and develop better drugs to treat
disorders linked to MATs.7
MATs are membrane proteins that span across the cell membrane lipid bilayer 12
times; the polypeptide N- and C- terminals are in the cytoplasm (Figure 1.1).
Experimental studies such as scanning cysteine accessibility mutagenesis (SCAM) were
carried out on these proteins to elucidate the mechanistic details of substrate translocation
and ligand binding. Computational efforts were performed to understand the atomistic
details of these proteins. Briefly, these studies can be divided as “pre-LeuT and postLeuT” and are described below. Leucine transporter (LeuT), a bacterial transporter
homologous to MATs, was crystallized in 2005. 8 Proteins evolutionarily distant from the
neurotransmitter sodium symporter family (NSS) were also used as templates to build the
1

homology models of MATs, but were later found to be poor tools as the homology was
very weak.8

Pre-LeuT based MAT efforts were ligand-based and included QSAR

studies, ligand-based pharmacophores that were used in virtual screening (VS) efforts to
identify novel compounds.
As of now, LeuT is recognized as the closest relative to these MATs, and is
shown to have an inverted symmetry between the two domains that are formed by six
transmembrane helices each. Only two conformations of the leucine substrate
translocation cycle (Figure 1.2), one with open-to out and the other being ligand bound
(occluded) were crystallized. The inward-facing conformation is the critical missing
piece of the puzzle.
A clear understanding of the MATs conformational transitions during the
substrate translocation will help in the design of better drugs. Different MAT homology
models were constructed using the two available conformations of LeuT. The homology
models were employed in various studies to discern the mechanism of action of various
MAT inhibitors that led to opposing conclusions. 9,

10

There is a dearth of structural

diversity in the MAT inhibitor ligands, and no studies were performed to identify novel
ligands with increased potency and reduced side effect profile. Recent structure-based
efforts have identified diverse novel compounds (hits) that can be optimized further as
leads (inhibitors) that bind to MATs.11-13
The following is a review of the computational efforts of MAT homology model
construction, their use in understanding MAT dynamics, substrate translocation, inhibitor
binding and especially the identification of novel scaffolds through virtual screening.

2

Extracellular

Intracellular

Figure 1.1. MATs embedded in lipid bilayer. hSERT (green helices) is embedded
within a POPE lipid bilayer (Van der Waals spheres) with both polypeptide terminals
within the intracellular space. Lipophilic tails (gray) of the phospholipids are oriented
toward the center of the cell membrane, arranged tail-to-tail; the polar head groups
containing phosphorous (pink), oxygen (red) and nitrogen (blue) atoms are oriented
toward the hydrophilic borders of the membrane. The S1 (yellow) and S2 (cyan)
substrate binding pockets are displayed as surfaces.

3

Figure 1.2. The three minimally required conformations of substrate translocation
cycle. TMs 1,3,6,8 that form the substrate translocation pore are presented as bars. The
outward facing conformation opened towards extracellular space allows the entry of
substrate (S) and ions (Na+) into the protein to form the occluded conformation. The
inward facing conformational transition is achieved with the release of substrate and ions
into the cytoplasm.

4

1.2 Generation of MAT Homology Models
1.2.1 Pre LeuT
Despite the lack of a closely related protein crystal structure, MAT homology
models were attempted as early as 1994, without the use of a structural template. A DAT
model was generated using the combination of 1) multiple sequence alignment (MSA) of
10 neurotransmitter sodium symporter (NSS) transporter cDNAs (hDAT, hNET, hSERT,
hGABA, rGABA, rGLY, rTAU, rCHO, rSERT and dog betaine) and 2) hydropathy plots
to assign TM domain length.14 The DAT homology model was used to discuss the
mechanism for substrate/ion binding and cocaine inhibition of the dopamine uptake.14 A
template-independent SERT homology model also employed MSA and hydropathy plots,
using online servers- PHD Predict Protein,15 DAS,16 TMpred and TopPred2.17 A cocaine
binding pocket was created in SERT with five TM helices using the data from ligand
binding and site-directed MAT mutagenesis.18 The remaining seven TM domains were
positioned and refined by electrostatic calculations using the electrostatics program
GRASP. Follow up docking studies with this SERT model suggested that citalopram and
cocaine interact with the charged side chain of D98 (TM1), while the TCA imipramine
bind elsewhere.18 The TM domain juxtapositions in the generated homology models were
largely speculative and not particularly accurate, owing to the lack of a template of 12
TM domain transporters.
The first template-based MAT models were constructed using the 12 TM
facilitated diffusion transporter with sequence identity 13% or less. MAT models were
derived from the mutational data of two such E. coli proteins, the Na+/H+ antiporter
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(NhaA) and the lactose permease (LacY), with the NhaA electron density projection map
serving as a template.19 The resultant MAT models were used to localize citalopram and
cocaine binding as well as the identification of substrate permeation pathway.20-22 It was
proposed that Y95 (TM1) of SERT to be responsible for the selectivity of the Senantiomer of citalopram (CelexaTM); the analogous residue was implicated in DAT
binding of cocaine and its analogs.21 A final round of non LeuT-based MAT homology
models employed an inward- (cytoplasm-) facing LacY crystal structure as a template.23
The LacY, best characterized of all membrane transporters, is a 12 TM protein with six
TM helices in each domain.24 Upon creating an inward-facing SERT model, an outwardfacing conformation was generated through a rigid body rotation of ~60° of both the
domains. The SERT conformation thus generated was later used to build the outwardfacing DAT and NET models. The MAT models thus developed were utilized to dock
cocaine, amphetamine and citalopram to identify the potential inhibitor binding sites.25
Unfortunately, the X-ray structures of NhaA and LacY were later found not to
appreciably resemble that of a true MAT homolog, the bacterial leucine transporter LeuT.

1.2.2 Post LeuT (2005 - present)
The publication of a crystal structure (pdb id: 2a65) of the leucine transporter
(LeuT) from Aquifex aeolicus,8 a thermophilic bacterium, provided the first reliable MAT
template for computational studies as it is the closest prokaryotic orthologue to the NSS
family.26,

27

The LeuT crystal structure launched a wave of new MAT models that

continue to be corroborated by biophysical studies. Several additional LeuT crystal

6

structures with inhibitors bound were also crystallized. 28-31 Unless otherwise specified,
the models discussed herein were based on the first available LeuT crystal structure (pdb
id: 2a65).

1.2.2.1 Dopamine Transporter (DAT)
Several DAT models were constructed using the LeuT as a template (Table 1.1),
but the first LeuT-based DAT model was reported by Huang et al. in a study of dopamine
interaction with the transporter and the substrate permeation pathway. 32 Binding free
energy calculations on the proposed binding mode of dopamine in DAT were in close
agreement to the experimental free energy observed in this study.32 Additional molecular
dynamic (MD) studies with this DAT model suggest that cocaine initially binds to a site
that is distinct from that of the dopamine binding site.33 In stark contrast, Beuming et al.
used a DAT model and a new multiple sequence alignment (MSA) to suggest that
cocaine, benztropine, and amphetamine bind in the primary substrate site also referred to
as S1.34 Mutagenesis and intramolecular cross-linking studies performed on DAT also
supported this proposal.35
Following this, a study by Indarte et al. elaborated the dopamine binding in DAT
indicating the likelihood of a primary and a secondary substrate site known as S2. This is
the first report that indicated the presence of two distinct binding sites (Figure 1.3)10. The
same study docked dopamine and d-amphetamine into three different rDAT models, and
from the results it was evident that in addition to the primary binding site, a secondary
extracellular pocket exists. It was proposed as the secondary substrate site that acts as a
temporary staging area for substrate translocation and a potential site for inhibitors. 10

7

Xhaard et al. proposed an alternate binding mode for substrates by docking
dopamine, norepinephrine and serotonin into the S1 site of DAT, NET and SERT
homology models respectively.

Additionally, the study proposed that the aromatic

hydroxyl substituent chelates with the Na1 in the pocket known as the “chelation mode”
as opposed to an interaction between the amine nitrogen and the Na1 in the “ionic
mode”.36

8

Figure 1.3. Ligand-accessible regions of MATs (SERT). Pocket space available to the
ligands in the deeper S1 (yellow) and the extracellular S2 (cyan) pockets are displayed as
surfaces. Selected residues that define each pocket are displayed as sticks (atomtype
color). For clarity, only the main TM contributors to SERT ligand binding pockets are
highlighted: TM 1 (pink), TM 3 (green), TM 6 (gold), TM 8 (brown) and EL 4 (blue).
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A number of MAT homology models were constructed using Beuming sequence
alignment.34 The alignment was generated using 344 NSS family proteins, and most of
the studies utilized models based on this comprehensive alignment (Figure 1.4).
Guptaroy et al. used a DAT model to study the local conformational changes associated
with a T62D mutation. The highly conserved T62 residue is located in the N-terminal
region, and the mutation of T62 favored the inward-facing conformation of DAT
suggesting a substantial role in the substrate translocation cycle. 37
Schmitt et al. generated a DAT model based on the desipramine-bound LeuT
crystal structure (pdb id: 2qju) to study the interaction profile of bivalent
phenethylamines.38 The docking studies suggested that the long flexible phenethylamines
span the substrate translocation pore of the protein, simultaneously occupying the S1 and
S2 pockets. The W84L and D313N DAT mutants also suggested that phenethylamines
prefer inward-facing DAT conformation, and further concluded the presence of multiple
low-affinity substrate sites throughout the translocation pore.38
In a study focused on MAT-inhibitor interactions, the electrostatic potential
surface for DAT was calculated, by docking cocaine and clomipramine into S1 and S2
sites respectively.39 In a recent study by Hong et al. four residues were identified for
SCAM studies, which led to the conclusion that DAT prefers the outward-facing
conformation in a cholesterol-rich lipid environment.40

10

Figure 1.4. Sequence alignment of hDAT, hNET, and hSERT amino acid sequences
aligned to LeuT following Beuming alignment. Residue position in the chain is
indicated with numbers (red) before and after each row. Predicted TM regions are
indicated above each sequence row. Identical (blue) or similar (yellow) residues across
all sequences are highlighted. Gaps between sequences are exhibited with dots.
Residues forming the extracellular charged gate (blue spheres), extracellular hydrophobic
gate (red stars) and the cytoplasmic charged gate are indicated below the sequence rows.
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Author

Year

Template
(PDB ID)

Sequence
Alignment

Edvardsen
Ravna
Ravna

1994
2003
2006

Developed
Developed
Developed

Huang
Indarte

2007
2008

None
NhaA
LacY
(1pv6)
LeuT
LeuT

Sequence
Identity
(%)
7
5

Software

Developed
Developed

20.4
-

Xhaard

2008

LeuT

Developed

-

Beuming

2008

LeuT

Beuming

20

Insight II
MOE, Robetta
3D-JIGSAW
Malign,
MODELLER
MODELLER

Guptaroy

2008

LeuT

Beuming

20

MODELLER

Ravna
Schmitt

2009
2010

Beuming
Beuming

20
20

Hong

2011

LeuT
LeuT
(2qju)
LeuT

Developed

-

ICM
MODELLER,
MOE
Swiss-Pdb
Viewer

MIDAS
MIDAS plus
ICM

(-) information not provided
Table 1.1. Construction of DAT homology models in chronological order.
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1.2.2.2 Serotonin Transporter (SERT)
Of the three MATs, most of the computational focus was on SERT, and so
numerous homology models were constructed (Table 1.2). Ravna et al. reported the
construction of first SERT model, which was used to identify amino acid residues
involved in ligand binding.41 Using the ICM pocket finder, a pocket formed by TM 1, 3,
6, and 8 that corresponds to the leucine binding site in LeuT was identified. 41
Subsequently, a similar conclusion was reached by a study in which LeuT and SERT
substrate binding sites were compared. 42 Additionally, the study suggested that the larger
serotonin substrate may be accommodated in a large pocket with smaller side chains, and
proposed the importance of D98 (TM1) in SERT for substrate interaction. 42
To further their understanding of the previously reported SCAM data,43 both
Zhang et al. and Rudnick et al. utilized a SERT model to propose that the residues in
TM5 may be involved in substrate permeation pathway.44 In a similar SCAM study, the
role of TM7 was also examined by correlating computational insights with the SCAM
data.45 Through these studies, it was proposed that TM7 was involved in ion dependence
and translocation pathway, possibly through the rotation of TM7.45

With a similar

rationale, a SERT homology model was used to support the results from Zn+2 binding
experiments, wherein the data suggested that residues in TM1 and TM3 were in close
proximity and oriented towards each other, especially V102 and I179. 46 To determine the
importance of the N-terminus in amphetamine action, a SERT homology model was
developed by Sucic et al. The study concluded that the N-terminus was involved in
substrate efflux by acting as a lever that reverses the substrate transport in the presence of
amphetamine.47
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A SERT homology model was generated and used by Jorgensen et al. to identify
the potential binding site of escitalopram by docking. The study concluded that the
binding mode observed was well in agreement with the already available mutagenesis
data.48 In a study focused on buspirone binding at SERT, two hSERT models were
constructed based on the inward-facing LacY (pdb id: 1pv6) and the outward-facing
LeuT.49 Various buspirone analogs were then docked into both the SERT models to
ascertain the residues involved in binding. The two distinctive models illustrated the
differences in the binding pocket environment created by different conformational states.
Specifically, in the LeuT-based SERT model, two binding sites were identified
corresponding to high- and low-affinity sites in LeuT.49
In an eloquent study, the paired mutant-ligand analogue complementation
(PaMLAC) method was used to study the binding of serotonin in the SERT primary
substrate pocket.50 In this study various serotonin analogs were docked into the final
SERT model using an induced fit method. The docked poses were experimentally
analyzed by coupling with mutational data generated from thirteen different single point
mutants, which concluded that serotonin interacts with D98, A173 and T439 residues. 50
A more recent study on the substrate binding by Kaufmann et al.
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suggested that 5-HT

binds in a different orientation, similar to the one proposed by Jorgensen et al. 48
Kauffman et al. built human and drosophila SERT models to identify the
differences conferring species selectivity. Different 5-HT analogs were docked; and the
most favorable pose oriented 5-HT in a “down” binding mode. The indole nitrogen is
located near Y176/Y171 residue pointing toward the interface between TM3 and TM8.
This was well in agreement with SCAM and mutagenesis data. 51 A SERT model was
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utilized to examine the substrate binding, where several 5-HT analogs were docked into
S1 site, and molecular dynamics was performed on the selected protein-ligand
complexes. The study concluded that IL1 and TMs 6, and 8 play an important role in the
substrate translocation.52
Binding of TCAs to the SERT was studied by using a model constructed using
open-to-out conformation of LeuT (pdb id: 3f3a).28 Analysis of the docked poses showed
protein-ligand interactions that were in agreement with site-directed mutagenesis data,
suggesting the presence of a vestibular low-affinity binding site for TCAs. The tricyclic
ring of the TCAs occupied the S2 vestibular pocket, while the amine tail probed into S1
site in the generated poses.53 Using both the open-to-out LeuT (pdb id: 3f3a) and the
occluded conformation (pdb id: 2a65), different SERT models were developed to study
inhibitor binding.

The high affinity S-enantiomer of citalopram (escitalopram) was

docked into SERT S1 site, and 64-point mutations were created to experimentally
analyze the docked poses. Docking into S2 was not considered in this study because
previous mutational studies for nonconserved residues in this region did not produce a
significant biological effect.54 Andersen et al. proposed two new residues, N177 and
F341, in S1 to be critical for the escitalopram binding.55
Most recently, Manepalli et al. utilized a SERT model as a tool for drug
discovery.13

In this study SERT models were developed based on four different

alignments: Yamashita, Beuming, Celik, and the Manepalli alignment, a modified Celik
alignment. The Manepalli alignment based model was used later for in silico virtual
screening (VS) of a subset of ZINC database to identify novel chemotypes. Furthermore
the use of this model in optimizing a previously identified hit was also reported

15

recently.12 Herein, docking and flexible alignment studies were used to guide the
chemical transformation of a non-selective MAT inhibitor into a SSRI. 12
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Author

Year

Template
(PDB ID)

Sequence
Alignment
Developed
Developed
Developed
Developed

Sequence
Identity
(%)
80
7
5

Ravna
Ravna
Ravna
Ravna

2001
2003
2006
2006

Ravna
Zhang
Henry
White
Jørgensen
Forrest
Xhaard
Jarończyk

2006
2006
2006
2006
2007
2007
2008
2008

Celik
Kaufmann

2008
2009

DAT
NhaA
LacY
(1pv6)
LeuT
LeuT
LeuT
LeuT
LeuT
LeuT
LeuT
LacY
(1pv6)
LeuT
(2a65)
LeuT
LeuT

Ravna
Sarker

2009
2010

Andersen

2010

Wenthur
Sucic
Gabrielsen
Manepalli

2010
2010
2011
2011

LeuT
LeuT
(3f3a)
LeuT
(3f3a)
LeuT
LeuT
LeuT
LeuT

Software
PHD, WHATIF
ICM
ICM
ICM

Developed
Beuming
Yamashita
Yamashita
Developed
Beuming
Developed
Developed

20
20
20.5
20.5
20
-

ICM
SCWRL
MODELER
NEST
Malign
ICM, Bioedit

Developed
Beuming

22.9
17

Beuming
Beuming

20
20

MODELER
ROSETTA
suite
ICM
MODELLER

Beuming

20

MODELLER

Beuming
Beuming
Beuming
Developed

20
20
20
23.9

MODELLER
MOE 2007.08
ICM
DS 2.5.1

(-) information not provided.
Table 1.2. Construction of SERT homology models in chronological order.
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1.2.2.3 Norepinephrine Transporter (NET)
In the past, NET was not given enough attention as compared to DAT and SERT,
however with the promising results of norepinephrine reuptake inhibitors (NRIs) and
dual-acting norepinephrine-dopamine reuptake inhibitors (NDRIs), attention to NET is on
the rise (Table 1.3). Aside from the NET models built by Ravna et al. along with SERT
and DAT models, few attempts have been reported. 22, 25, 56-58 A NET homology model
was generated to visually examine the effects of mutations on the binding of TCA
desipramine and conopeptide χ-MrIA, a noncompetitive, selective NET inhibitor. 56
Several residues presumed to be important for χ-MrIA interactions were located near the
extracellular pocket of the transporter. Correlating the mutagenesis data along with
docking studies, it was concluded that the binding sites of the conotoxin and TCA
overlap while the conotoxin and norepinephrine sites are discrete.56
In a similar unpublished study by Nolan et al. two distinct binding pockets were
identified using a NET model based on the open-to-out LeuT crystal structure (pdb id:
3F3A). Adaptive Poisson-Boltzmann Solver (APBS) calculations of docked poses for
known NET ligands were compared to experimental data, which concluded that a
secondary site exists in the vestibular region of NET where inhibitors bind, particularly
the TCAs. In a study on NET ligand binding, Hill et al. used previously built DAT model
32, 33

as a template to construct a NET model, as there is a high similarity (67%) between

DAT and NET.57 NE was docked into the S1 site and MD simulations were carried out
on the resulting NET-NE complex to examine the influence of cocaine and its analogs,
RTI-33 and RTI-113, on substrate binding. The study concluded that cocaine occupies a
pocket far removed from the S1 substrate site. 57 A recent effort to identify the
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determinants conferring inhibitor selectivity for SERT and NET was performed. 58 Herein,
the structural details of SERT/NET selectivity were studied for citalopram and talopram,
an SSRI and NRI respectively.

Mutational data from this study suggested that the

binding pocket of SSRIs overlap the S1 pocket whereas talopram binds at a distinct site. 58
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Author

Year

Ravna
Ravna
Paczkowski

2006
2006
2007

Hill
Andersen
Nolan
(unpublished)

2011
2011
2011

Template
(PDB ID)
NhaA
LacY
LeuT

Sequence
alignment
Developed
Developed
Beuming

Sequence
Identity (%)
7
5
20

DAT
LeuT
LeuT
(3f3a)

Beuming
Beuming
Beuming

66
20
20

Software
ICM
ICM
MODELLER
Insight II
DS 2.5.1,
APBS

(-) information not provided
Table 1.3. Construction of NET homology models in chronological order.
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1.3 Molecular Dynamics (MD) on MATs
1.3.1 DAT Dynamics
Of the three MATs, DAT and SERT were the most studied, which may be due to
their involvement in several disease states. Molecular dynamics simulations were
performed on DAT models even before LeuT was crystallized. Edvardsen et al.
calculated the interaction energies of DAT complexes with the substrate dopamine and
two enantiomers of the psychostimulant cocaine. 14 Another study performed by Ravna et
al. later concluded that changes in TM helical arrangement constricted the translocation
pathway suggesting tropane analogues cannot fit in the putative ligand pocket. 20
The first full-fledged MD study on DAT models constructed using LeuT was
performed by Huang et al.32 Molecular dynamics on both apo DAT and DAT- dopamine
complex were performed to localize the substrate-entry pathway. The calculated strength
of dopamine binding to DAT evaluated by molecular mechanic/Poisson-Boltzmann
surface area (MM-PBSA) was -6.4 kcal/mol that was similar to the experimental binding
energy (-7.4 kcal/mol).32 Following this study, several DAT complexes were generated
by docking ligands like dopamine, amphetamine, cocaine and its analogues, benztropine
and its analogues into DAT.9 Of the different complexes generated, the complexes of
DAT-CFT (a cocaine analog) and DAT-DA were studied further using MD simulations.
Using mutagenesis studies, intramolecular cross-linking studies, docking and molecular
dynamics, it is proposed that cocaine and its higher affinity analog WIN-35,248 can go
deeper into DAT and occupy S1 substrate pocket which was not shown previously. 35
The effect of mutation of a highly conserved T62 residue in the N-terminal of
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hDAT in the [RETW] motif on dopamine uptake was studied using free energy
perturbation (FEP) and mutational studies. The study concluded that T62 holds DAT in
an open to outward conformation towards the extracellular space favoring dopamine
uptake.37 Huang et al. extended their previous MD studies32 on DAT to explain the
mechanism of cocaine inhibition on dopamine uptake.33 The study concluded that
dopamine and cocaine bind at discrete non overlapping pockets and cocaine decreases the
kinetic turnover of DAT by binding in the extracellular pocket.33 The conclusion of this
study directly contradicted the study performed by Beuming et al. which proposed a
single overlapping binding site for cocaine and dopamine.9
Gedeon et al. performed dynamics on DAT homology model constructed using
LeuT. The study concluded that the extracellular salt bridge R85 (TM1) – D476 (TM10)
is formed less frequently in the presence of a substrate at S2. 59 Biased steered molecular
dynamics was performed by applying a force to dopamine and pulled in both the
extracellular and intracellular ways to identify the whole permeation pathway. 60 A
stopover site towards extracellular space corresponding to S2 pocket was identified. The
study was extended further by placing a second substrate molecule in the S1 pocket,
which finally concluded that the presence of a second substrate molecule in the S2 site
had an allosteric effect on the substrate in S1 pocket, causing it to get released into the
cytoplasm.60
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1.3.2 SERT Dynamics
The first full-fledged dynamics on SERT employed complexes of the SERTserotonin and SERT-escitalopram generated using docking. 61 It was shown that the
extracellular hydrophobic gate residue Y176 would embrace different conformations to
better accommodate the changes in the binding pocket.61 Following this study, dynamics
was performed to verify whether the SERT model constructed using LacY would convert
to SERT built using LeuT. It was noticed that there was no impact on the helical packing
of SERT based on LacY, and did not resemble the SERT model constructed using
LeuT.49
MD studies on the models of wild type SERT, T81A and T81D mutants were
performed to focus on how the N-terminus (Thr81) would influence the SERT
conformation.47 It showed the incidence of intracellular structural changes resulting in the
opening of intracellular vestibule. The same study also showed that the mutation of T81A
would induce an inward facing conformation by increasing the distance between the
terminals. This equilibrium shift towards increased SERT inward facing conformation
favored the amphetamine-induced efflux of 5-HT. The equilibrium hypothesis was tested
experimentally by the removal of first 64 residues at the N-terminus, and tethering of Nterminal completely obliterated the amphetamine induced substrate efflux. The final
conclusion of this study was the importance of the N-terminus, which induces
conformational changes by acting as a lever.47
The trajectory analysis of molecular dynamics performed on SERT showed a
substantial movement of TM7 especially, the M370 and S375 residues.45 SCAM studies
were followed up to identify the residues that are exposed towards the hydrophilic

23

environment. The combined analysis of MD and SCAM suggest the importance of TM 7
in addition to TMs 1, 3, 6 and 8. The same SERT homology model also identified
residues, V366 and M370 exposed towards the lipid bilayer, thus reducing their
accessibility towards the MTSEA reagents. Finally, they concluded that Na ion exodus
rotates TM7 to expose V366 and M370 towards MTSEA reagents.45
An effort to study the substrate translocation in SERT was launched recently. 52
Different SERT complexes of apo SERT, SERT-serotonin and SERT-escitalopram were
generated and MD was performed. Careful analysis of the MD trajectories showed that
SERT adopts different conformational changes that assist in the substrate translocation. 52
Koldsø et al. performed the longest MD simulations on SERT. 62 The study identified that
the outward facing single substrate-bound SERT complex transformed to an inward
facing conformation thus strengthening the claim of the absence of allosteric effect. The
doubly bound substrate complex in SERT did not show any signs of the substrate
translocation; rather, the loosely bound substrate got dissociated towards extracellular
pocket. The role of D437 residue in ion transport was shown along with the hydration of
substrate and Na2 ion, which is the ion that gets released into the cytoplasm.62

1.4 Ion (Na+, Cl-) Binding Sites
Structure-based computational efforts were directed towards identifying the
binding sites for two Na+ and one Cl- ion, the essential components for monoamine
transporter function (Figure 1.5). While residues interacting with two bound Na+ ions in
LeuT crystal structures were conserved amongst the NSS proteins (Figure 1.6), little was
known about the binding domain of the Cl- ion, as it is not essential for many NSS
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members including the LeuT, Tyt1 and TnaT. With this, a SERT homology model was
developed in an effort to elucidate the Cl- ion-binding site in MATs.63 The negatively
charged residues in LeuT that may replace the role of Cl- ion in the MATs were
identified using the Multi-Conformer Continuum Electrostatics (MCCE) method. It was
identified that the E290 of LeuT was nonconserved among Cl- dependent transporters,
corresponding to a serine in the MATs (S372 in SERT). The placement of a Cl- ion at
this position in the SERT model showed coordination between the hydroxyl and amine
hydrogen’s of Y121, S336, N368, S372 and is in close proximity to Na1 (~5Å)
suggesting that Cl- at this position would stabilize the binding of Na1 ion.
Experimentally, the S372 and N368 mutants displayed decreased function and moreover,
the substitution of these residues with a negatively charged residue produced a Cl- ion
independent transporter with reduced activity. 63 Similar experimental studies support
these findings that likewise suggest that a Cl- ion or a negatively charged residue is
required for transport.64, 65
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Figure 1.5. The top view of proposed ion binding sites in MATs (SERT). The
residues of helices, TM1(yellow), TM2(blue), TM6(pink), TM7(brown) and TM8 (red)
that interact with substrate(green sticks), sodium (orange) and chloride (green) ions are
displayed as sticks.
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Figure 1.6. The close-up view of the ion-binding sites in MAT (hSERT). Substrate
(green sticks) Na+ ions (orange spheres) and Cl- ions (green spheres) are displayed. The
residues interacting with these ions are presented as sticks in atom type color and the
corresponding residues in DAT (blue), NET (red) and SERT (green) are shown.
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1.5 Virtual Screening
In addition to homology models, ligand-based models were proven useful in the
study of transporter interactions and ligand recognition. Prior to the availability of NSS
crystal structures, computational approaches relied heavily on known MAT ligands and
their associated structure-activity relationships (SAR). A few caveats exist with 3D
ligand-based studies including the assumption that all training set compounds bind at the
same site of the same protein in a similar conformation.

1.5.1 Ligand-Based VS
While most ligand-based models have served to define the necessary features
common to known ligands, some of these models were applied in the search for potential
new scaffolds through virtual (in silico) screening.

An early ligand-based virtual

screening study on the DAT featured a pharmacophore model based on just two
compounds, cocaine and WIN-35065-2.66

The model consisted of three features: a

nitrogen atom, a carbonyl group and an aromatic ring. Screening of the National Cancer
Institute (NCI) database afforded 4094 compounds from which 44 out of the 70 tested
experimentally were proven to inhibit DAT at 10 μM. The most potent of these hits
exhibited an uptake inhibition potency of 274 nM, 155 nM, and 108 nM at DAT, SERT,
and NET respectively.66 An analogue of the quinuclidine scaffold was identified as a
novel DAT inhibitor in a different study.67 Following the analysis of known DAT
ligands lacking a carbonyl atom, the pharmacophore model already proposed was refined
to include two additional features- an aromatic group and a tertiary amine. 68 Screening of
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the Advanced Chemical Dictionary (ACD) database with the modified pharmacophore
model resulted in the identification of eight hits with IC50 values less than 10 μM.68
Applying slight modifications to the distance constraints between the nitrogen
atom and two aromatic features, the model afforded indole class of compounds with a
NET and SERT affinity of 137 nM and 126 nM respectively.69 In response to the report
that a tertiary nitrogen in tropane analogs was unnecessary,70 Enyedy et al. refined
existing model by substituting a hydrogen-bond acceptor to tertiary nitrogen. The refined
model was used for screening the NCI database that resulted in 1104 hits. Experimental
testing of these compounds identified two hits with DAT uptake inhibition potency of 2.3
μM and 0.255 μM respectively.71 A similar pharmacophore was derived from mazindol
that consists two lipophilic aromatic rings along with one nitrogen atom. The
pharmacophore was used to screen the ACD database containing 225,000 compounds
which identified three compounds with Ki values of 128 nM, 48 nM and 24 nM,
respectively.72
Using an undisclosed VS method, a potent NET-selective compound with an
uptake inhibition potency of 1 nM was identified.73 A pharmacophore model for NET
was generated by studying the conformations adopted by milnacipran in solution and
used in the design of analogs with better pharmacological profiles at MATs. 74 The
generation of a pharmacophore model based on the NET-selective χ-conotoxin, a peptide
component of marine cone snail venom resulted in the design of a compound which has
entered phase II clinical trials.75
In an effort to compare the necessary features for activity amongst MATs,
different pharmacophore models were generated separately for each transporter using a
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training set containing either tropane analogs or GBR-12909 like compounds. The study
highlighted the similarities as well as differences in the potential binding modes by
coupling structures with biological activity. It was suggested that minor modifications to
a core scaffold can confer selectivity for one transporter over the others. 76 A study was
attempted to differentiate the pharmacophore features necessary for SERT and D 2
receptor binding among a series of dual-acting piperazine ligands. The SERT
pharmacophore model consisted of basic nitrogen, a sterically restricted area around the
nitrogen, an aromatic region, and a general hydrophobic region.77 While these
pharmacophore features were the same as those of the D2 receptor, the three dimensional
arrangement of features differed, suggesting the flexibility of dual ligands vital for
adopting different conformations to bind these two proteins. 77

1.5.2 Structure-Based VS
The utility of MAT homology models was not limited to mechanistic and binding
studies. Recent reports demonstrate the value of using these models for the identification
of novel chemotypes.11,

13

To date there have been only two reports describing the

discovery of novel MAT ligands through structure-based virtual screening wherein both
have focused on the extracellular vestibular region (S2). 11, 13 The first DAT-based VS
approach used a structure-based S2 pharmacophore to screen a chemical database
containing over 140,000 compounds. Ten final compounds were selected based on the
score (Affinity dG in MOE), predicted pKi, and visual inspection to be
pharmacologically tested for activity at the MATs. MI-4, an ifenprodil analog, was
discovered to have affinity at all three transporters.11
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The first structure-based VS on SERT was approached more recently using a
pharmacophore developed from S2 and halogen binding pockets (HBP).13 Herein, a
subset of the ZINC database (~ 1 million compounds) was screened using highthroughput docking in MOE. Visual inspection along with the Affinity dG score aided in
the selection of hit compounds for pharmacological analysis. This study resulted in three
structurally novel compounds, two selective SERT ligands (SM-10 and SM-11) and one
DAT selective compound (SM-14) with no affinity towards the other transporters in both
the cases.13 The SERT model was equally used to refine a hit compound (MI-17)
identified through the DAT VS study to create a more selective SSRI (MI-17 hybrid).12
The first NET-based VS effort employed S1 pocket to screen Kyoto Encyclopedia of
Genes and Genomes (KEGG) drug database containing 6436 known drugs. Ten of the
final eighteen hits showed micromolar affinity towards NET. The study was more like
drug repurposing for already known molecules and not a pure VS approach to identify
novel compounds.
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Figure 1.7. Different approaches used in virtual screening to identify novel scaffolds.
Ligand-based methods use models that employ different pharmacophore features labeled
F1-F5 with a volume constraint to screen a small molecule library. Structure-based
methods filter through virtual small molecule libraries to identify hits (orange spheres) by
docking them into the binding pockets of MATs (green helices). Hybrid approaches use
ligand-based VS followed by structure-based VS.
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Name

Structure

Binding affinity (Ki (nM))
hDAT

hNET

hSERT

3460±260

365±68

670±100

SM-10

ND

ND

38,000±17000

SM-11

ND

ND

17,000±7000

SM-14

15,600±2400

ND

ND

MI-17

1298±36

5300±1341

284±66

MI-17

2129±177

>10,000

37±4

MI-4

hybrid

Table 1.4. Novel MAT ligands discovered through MAT virtual screening.
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1.6 Conclusion
Structure-function studies performed on MATs were limited by the experimental
techniques; and the recent computational efforts have proven highly valuable in
understanding the functioning of these transporters more closely. The computational
efforts to understand atomistic aspects of MAT function provided more structural clues in
the design and development of new drugs. The design of novel drugs to treat various
neurological disorders so far lacked a structural direction. Thus the structure-based VS
efforts on MATs were undertaken, which led to the discovery of novel chemo types; and
hit-to-lead optimization of these chemotypes helped increase their potency profile.
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Chapter 2.
DISCOVERY

OF

NOVEL

SELECTIVE

SEROTONIN

REUPTAKE INHIBITORS THROUGH DEVELOPMENT
OF A PROTEIN-BASED PHARMACOPHORE†
† Reproduced in part with permission from Manepalli, S.; Geffert, L.M.; Surratt, C.K.; Madura, J.D.
J Chem. Inf. Model. 2011, 51(9), 2417-2426.

The serotonin transporter (SERT), a member of the neurotransmitter sodium
symporter (NSS) family, is responsible for the reuptake of serotonin from the synaptic
cleft to maintain neurotransmitter homeostasis. SERT is established as an important
target in the treatment of anxiety and depression. Because a high-resolution crystal
structure is not available, a computational model of SERT was built based upon the x-ray
coordinates of the leucine transporter LeuT, a bacterial NSS homolog. The model was
used to develop the first SERT structure-based pharmacophore. Virtual screening (VS)
of a small molecule structural library using the generated SERT computational model
yielded candidate ligands of diverse scaffolds. Pharmacological analysis of the VS hits
identified two SERT-selective compounds, potential lead compounds for further SERTrelated medication development.

2.1 Introduction
Signaling between cells in the central nervous system is mediated by the
controlled release and reuptake of neurotransmitters in the synapse. 1 An excess or deficit
of the monoamines serotonin, dopamine or norepinephrine in the synapse has been
associated with various psychiatric and neurological disorders including depression,
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anxiety, compulsivity, attention deficit hyperactivity disorder (ADHD), substance abuse,
Parkinson’s disease and schizophrenia.

2-7

Control of synaptic monoamine levels is

affected by the plasma membrane monoamine transporters (MATs), which terminate the
action of these biogenic amines via reuptake into the presynaptic cell. The mechanisms
of action of drugs related to the above medical conditions typically involve the MAT
proteins. Tricyclic antidepressants (TCAs) such as imipramine (TofranilTM), developed
in the 1950s, alleviate depression by blocking serotonin and norepinephrine transporters
(SERT and NET, respectively), thereby extending the lifespan of synaptic serotonin and
norepinephrine. Unfortunately, the TCAs also block adrenergic, muscarinic acetylcholine
and histamine receptors, responsible for a plethora of adverse effects. 8,

9

Selective

serotonin reuptake inhibitors (SSRIs), the next generation of antidepressants led by
fluoxetine (ProzacTM) in the 1980s, carry far fewer adverse effects compared to the
TCAs. The SSRIs block SERT, but because the resultant surge of serotonin can activate
any of 14 serotonin receptor types, this drug class is not without its own adverse
effects.10-12
The driving force for MAT uptake of monoamine substrate is electrogenic,
harnessing the inward Na+ gradient across the cell membrane. 13, 14 The SERT, NET and
DAT (dopamine transporter) are members of the neurotransmitter:sodium symporter
(NSS) family as well as members of a larger group of Na+ and Cl- dependent transporters
known as the "solute carrier 6" (SLC6) family. 15 The lack of a high-resolution 3-D MAT
structure had hindered structure-function and therapeutic development efforts until a
breakthrough was achieved in the form of crystallization of the bacterial NSS homolog
LeuT, a leucine transporter.16 The LeuT x-ray structure has provided a template to build
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credible MAT computational models.16-21

Although model quality increases with

sequence identity with the template, structural similarity also plays a significant role.
In the absence of high-resolution 3D structures for SERT, development of a
ligand based pharmacophore22-25 or QSAR26-28 are feasible alternatives to obtain
structural information about the binding pocket. Ligand-based approaches analyze a set
of ligands and generate possible protein-ligand interaction patterns without knowledge of
the protein structure. A limitation of ligand-based approaches is that flexible alignment
using dissimilar scaffolds is less reliable; knowledge of the bioactive conformation of at
least one active molecule significantly improves alignment accuracy. 29 These limitations
can be overcome by using structure-based approaches, in which diverse scaffolds can be
used to capture ligand interactions and the binding pocket environment in general.
Docking, a structure-based technique, is capable of reliably predicting the bioactive
conformation for a co-crystallized ligand.30

In the absence of an experimental 3D

structure, however, a reasonable 3D model can be constructed for a receptor using
crystallographic or NMR data from genetically and functionally related proteins. 31, 32
Comparative modeling correctly predicts the 3D fold of a protein in most cases
and has often provided insight into the atomistic details of ligand binding. 33, 34 Models
created by this method have identified potential binding pockets, and have been
employed for docking, structure-based pharmacophore generation and virtual screening
(VS) to identify new ligands and their interactions with the protein. 33,

35,

36

Pharmacophore models, defined as a 3D collection of features essential for bioactivity of
a ligand, have been widely employed. 37, 38 The approach of combining a pharmacophore
with VS has yielded novel structural scaffolds for ligands of a target receptor. 39-44
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Application of this technique with the DAT led to the identification of structurally novel
VS "hit" compounds which, upon further modification, created a more potent analog
through rational drug design.33, 43, 45 The present work describes the development of a
structure-based pharmacophore and its VS utilization to identify novel ligand structural
scaffolds that display SERT selectivity.

2.2 Materials and Methods
Molecular modeling studies were performed out using dual-core 3.06 GHz iMac
and 2.66 GHz quad-core Intel Xeon macpro. Construction and evaluation of homology
models were performed using Discovery Studio 2.5.1. 46 Docking and pharmacophore
studies executed using the modules in Molecular Operating Environment (MOE
2008.09); Chemical Computing Group Inc., S. S. W., Suite #910, Montreal, QC, Canada,
H3A 2R7.) [125I]-RTI-55 and [3H]-serotonin were purchased from PerkinElmer (Foster
City, CA).

The VS hit compounds were purchased from enamine and molport. The

N2A-hDAT cell line was a gift from Dr. Margaret Gnegy (University of Michigan).
HEK293 cells stably transfected with hSERT or hNET were prepared in collaboration
with Dr. Mads Larsen and Dr. Susan Amara (University of Pittsburgh, Pittsburgh, PA).
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2.2.1 Computational Methods
2.2.1.1 Sequence Retrieval and Integrity Check of
Template
The FASTA sequence of hSERT was downloaded from the Uniprot database
(accession number P31645).47 The X-ray crystal structure of the Aquifex aeolicus protein
LeuT (2a65) was used as the template and downloaded from the protein data bank
(PDB).48 The template was checked for any missing residues/atoms using the “protein
reports and utilities” module in DS 2.5.1. 46 The protein report generated is a compilation
of information about the resolution at which a protein was crystallized, the cell and space
group of the crystal, atoms/residues missing the coordinates. In addition, it also provides
a list of active sites, number of ligands, ions and solvent molecules cocrystallized with
the biomolecule. This report can be viewed as concise portrayal about the defects in a
crystal structure like nonstandard naming, structural disorder, atom connectivity and
incorrect bond order of the amino acid residues. The report indicated that the residues
Asn-133 and Ala-134 of the second extracellular loop (EL2) in LeuT (2a65) were
missing the coordinates. As EL2 was noticed to play an important role in transport by
forming the extracellular lid along with EL4 the coordinates of the missing residues in the
loop (EL2) were built into the template in DS16. Since the modeled residues were in a
loop, the most flexible regions in a protein, EL2 was subjected to the loop refinement
protocol in DS to optimize the generated loop region.

48

2.2.1.2 Different Sequence Alignments
SERT models were created even before LeuT crystallization, which is the closest
homologue to MAT family. Even though different alignments were developed using
LacY and other proteins as templates, the sequence alignments using LeuT as the
template gained more attention due to its close evolutionary relationship with MATs
(Table 2.1). Of these alignments, Yamashita et al. proposed the first alignment 16 using
Psi-BLAST49 with minor manual adjustments. No evolutionary information about MATs
was used in generating this alignment and was generated only for the following human
transporters--glycine, gamma-amino butyric acid, dopamine and serotonin leaving out
norepinephrine transporter from the alignment. Following this, Beuming et al. 50
proposed a comprehensive sequence alignment using 177 eukaryotic and 167 prokaryotic
protein sequences belonging to NSS family. The alignment considered evolutionary
conservation pattern along with wealth of biological data available for NSS proteins. It
considerably differed in TM 4,5,9 regions along with differences in EL 2,3,4 loops
compared to Yamashita alignment, and was the most used alignment for model
generation by different groups. Recently Celik et al. 51 built SERT models using the
proposed Yamashita’s and Beuming’s alignment along with an in-house developed
alignment. Even though Celik’s alignment was not as comprehensive as Beuming’s; it
considered residues Asp 98, Ala 169 and Ile 172 be pointing into the pocket and not into
the lipid-facing region. None of the alignments proposed so far explicitly mentioned
about modeling of the missing residues in EL2 that played a substantial role in substrate
translocation. This study involved generation of another alignment by using “align
sequence to template” protocol in DS. This protocol considers structural restraints into
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account in the search for common motifs among the sequences. Though all these
alignments looked similar in TM regions, minor differences are present in loop regions
that influence studies performed to study dynamic aspects of these proteins. The addition
of missing residues to LeuT used in alignment modified the sequence identity by a
marginal extent (24%) compared to other alignments, but it is regarded generally as the
more the sequence identity with the template used the better the model generated 52. The
objective of using all four alignments was to identify which alignment produces a model
suitable for our study.

Manepalli
alignment

Celik
alignment

Beuming
alignment

Yamashita
alignment

% Sequence
identity

23.9

22.9

20.5

20.0

% Sequence
similarity

46.7

45.6

42.6

42.4

Table 2.1. Percent sequence identity and sequence similarity among different
alignments used to build SERT models.
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2.2.1.3 Construction of SERT Homology Models
Different hSERT models were then created using the Align2d methodology53 and
the three previously proposed sequence alignments. 16, 50, 51

2.2.1.3.1 hSERT Model 1: Manepalli et al. Alignment
The sequences of hSERT and modified LeuT were aligned using the "align
sequence to templates" protocol in DS. An alignment similar to Celik et al. 51 was
generated, with minor manual modifications further increasing the sequence identity with
LeuT. N- and C-terminal overhangs were deleted, increasing sequence identity to 24%
and sequence similarity to 47%. The hSERT model sequence began at Arg-79 in the Nterminal tail and ended with Lys-605 in the C-terminal tail (Figure 2.1). The "build
homology model" protocol in DS, which employs MODELLER version 9v4, 31 was used
to construct 20 hSERT models. The models were further refined and ranked by discrete
optimized protein energy (DOPE) score and the model with the best DOPE score was
designated as “Model 1”.

51

Figure 2.1. Alignment of LeuTAa and hSERT amino acid sequences used to build
Model 1. Identical (blue) and similar (yellow) aligned residues are indicated. The dots
and stars correspond to residues lining S1 and S2 pockets respectively. Transmembrane
and connecting loop topology is displayed above the sequences. Gaps relative to the
other sequence are represented by dots. Position of the residue in its respective chain is
indicated before and after each line of sequence.
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2.2.1.3.2 hSERT Model 2: Beuming et al. Alignment
The hSERT query sequence and modified LeuT were loaded into DS and aligned
as described by Beuming et al. (Figure 2.2).50 Terminal residues not having the
matching template coordinates at both ends were omitted, and 20 models were built and
assigned DOPE scores as described above. Models based on this alignment resulted in
EL2 positioned directly above the substrate permeation pore, which would likely have
influenced ligand docking. The dangling EL2 was adjusted using the DS loop refinement
protocol. Models were then evaluated using the "verify protein" protocol, which assesses
the score of each residue in the known 3D environment. This was followed by
superposition of the hSERT model onto LeuT to check for TM domain coincidence. The
final version was designated "Model 2".

53

Figure 2.2. Alignment of LeuTAa and hSERT amino acid sequences following Beuming
alignment. Identical (blue) and similar (yellow) aligned residues are indicated. Transmembrane
and connecting loop topology is displayed above the sequences. Position of the residue in its
respective chain is indicated before and after each line of sequence.
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2.2.1.3.3 hSERT Model 3: Yamashita et al. Alignment
The hSERT query sequence and modified template were aligned as proposed by
Yamashita et al. (Figure 2.3).16 N- and C-terminal overhangs were deleted, leaving 527
hSERT residues. Twenty models were created and the best model resulting from this
alignment was designated as "Model 3".

Figure 2.3. Alignment of LeuTAa and hSERT amino acid sequences following
Yamashita alignment. Identical (blue) and similar (yellow) aligned residues are
indicated.
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2.2.1.3.4 hSERT Model 4: Celik et al. Alignment
Twenty hSERT models were built with DS as described above but following the
proposed Celik et al. alignment 51 (Figure 2.4), which offered a sequence identity match
comparable to the Manepalli alignment and greater than the Beuming and Yamashita
alignments. A 527-residue hSERT polypeptide was used to develop “Model 4”, as
described for Model 1.

Figure 2.4. Alignment of LeuTAa and hSERT amino acid sequences following Celik
alignment. Identical (blue) and similar (yellow) aligned residues are indicated.
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2.2.1.4 Model Refinement and Validation
Five models among the twenty homology models created from each alignment
were chosen based on Discrete Optimized Protein Energy (DOPE) scores. It is a score
generated by MODELLER, which is an atomistic-based statistical potential for model
evaluation and structure prediction.54 This conformational energy measure reflects the
stability of a model relative to other models generated. Following this, the stereo chemical
quality of the five preferred models was assessed with the validation server that is used to
evaluate structures deposited into PDB. 55 This server uses NUCheck56, PROCHECK57 and
SFCHECK58 programs to check various stereo chemical features that symbolize a
structure stability. From each group of five, two models were then chosen based on their
having the fewest outliers on the phi-psi angle Ramachandran plot. The chosen two
models from each alignment were evaluated for 3D fold (tertiary structure), using the
“verify protein” protocol in DS. This protocol reduces 3D structures to a simplified 1D
representation, compares to the 1D amino acid sequence, and assigns a score. This score
measures how compatible a three-dimensional fold is with its one-dimensional sequence.
If the score calculated is close to the expected high it implies that generated model has an
optimal 3D-fold respective to its sequence and lower scores highlight regions that are
poorly modeled and their fold is not optimal to its amino acid sequence. The models
selected from the previous evaluation parameters were checked for TM domain assembly
and ligand binding pocket volume by superposing the SERT models onto the LeuT crystal
structure using MOE (Figure 2.5).59
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Figure 2.5. Polypeptide backbone superposition of the four homology SERT models.
Good overall spatial overlap was observed for Models 1 (Manepalli et al.; red), 2
(Beuming et al.; blue), 3 (Yamashita et al.; yellow) and 4 (Celik et al.; green), with
essentially perfect overlap of TM domains. EL2 (arrow) was the most divergent region
among the four models.
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A single hSERT model was selected from each of the groups resulting in four final
models that were generated using different alignments.
AMBER99

60, 61

The all-atom force field

was used to add hydrogen atoms and partial charges to the models.

Keeping the non-hydrogen atoms fixed in space, hydrogen atoms were minimized with a
convergence criterion of 0.05 kcal/mol. The final hSERT models chosen from each
alignment were further optimized to minimize the outliers and avoid unnecessary protein
contacts. Of the four models, Model 1 had the smallest RMSD on superposition with
LeuT and maximal ligand binding pocket volume.

2.2.1.5 Ligand Binding Site Identification
The alpha site finder function of MOE 2008.09 was used to identify possible
ligand binding sites in Model 1. The site finder is purely geometric; no energy terms are
used. Alpha spheres within the hSERT model that were too exposed to solvent were
eliminated; spheres that corresponded to locations of tight atomic packing in the model
were retained.

Spheres were classified as either "hydrophobic" or "hydrophilic"

depending on the potential for hydrogen bonding. Following the default settings, alpha
spheres were clustered to produce a collection of putative binding sites that are ranked
according to the number of hydrophobic atoms within contact distance of the spheres. The
sites corresponding to the S1 and S2 pockets were identified and dummy atoms were
created in the pockets to specify the algorithm to dock the ligands. As the S2 pocket is a
huge cavity exposed towards the extracellular space, a sphere with a radius of 8 Å was
created to constrain docking poses in keeping with recent reports (Figure 2.6).18, 21
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Figure 2.6. A sphere (red) of 8 Å to constrain docking poses in extracellular exposed
S2 pocket. hSERT displayed as blue TM helices.
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2.2.1.6 Docking of Known Antidepressants
Ligand coordinates for sixteen antidepressants (Figure 2.7) were obtained from the
small molecule crystal database CCSD (Cambridge Crystallographic Structural
Database).62, 63 Ligands having no coordinates were drawn using MOE. Partial charges
and hydrogen atoms were added to all ligands using Merck Molecular Force Field 94X
(MMFF94x).64-66

Ligand geometry was optimized via energy minimization with a

conjugated gradient truncated Newton optimization algorithm with convergence criteria =
0.01 kcal/mol, ε = 1. Leucine or selected TCA drugs were first docked with the LeuT
model to test for consistency with the reported cocrystal structures. 16, 21 Atom placement
methods including proxy triangle, alpha triangle and triangle matcher were employed, as
were refinement techniques using grid-based and force field-based methods.

The

combination that produced poses very close to the crystal structure (<1Å) was chosen for
hSERT docking.

Interaction plots for all docked poses of different antidepressants in

hSERT were generated using the MOE ligand interaction module. 67 A consensus of
residues and their predicted ligand interactions was developed and used in creating the
pharmacophore features for the vestibular ligand-binding pocket.
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Figure 2.7. Chemical structures of SERT inhibitors (antidepressants) used to develop
the pharmacophore.

62

2.2.1.7 Development of 4-point SERT S2 Pharmacophore
A pharmacophore feature was generated at each amino acid side chain – ligand
interaction point obtained from initial docking iterations. Pharmacophore points F1, F2,
F3 (each with a radius of 1 Å) and F4 (radius = 1.5 Å) were delineated to better
encompass the hydrophobic features of the docked ligands. An excluded volume was
created, and the algorithm assigned a penalty to poses that encroached on this space. The
final pharmacophore product was tested using a database containing known hSERT
ligands and decoy ligands. The pharmacophore model successfully discriminated the
classic hSERT ligands from the decoys (Table 2.2).

Compound
Fluoxetine

Affinity dG Score
(kcal/mol)
-9.23

Sertraline

-9.05

Paroxetine

-8.92

Citalopram

-8.75

Fluvoxamine

-8.24

Zimeldine

-8.07

Venlafaxine

-7.67

Trazadone

-7.19

Imipramine

-6.87

Table 2.2. List of top ten compounds (binders) identified in the evaluation of
pharmacophore.
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2.2.1.8 Virtual Screening of ZINC Database
An 18 million entry “all-purchasable” subset of the ZINC database containing was
downloaded.68 The subset was “washed” by importing the collection into MOE, which
removes unwanted salts, ions and disconnected molecular fragments from the database.
The Lipinski’s Rule of Five descriptor available in MOE was applied to the database to
remove nondrug-like molecules.69

The resulting database was then searched for

compounds containing toxic groups and eliminated by using toxic moiety descriptor in
MOE. From this database a subset containing approximately one million compounds was
selected for further use. The tautomers and protomers of these entries were generated at
physiological pH.

Using the “import conformation” module of MOE, different

conformations were generated and minimized using the MMFF94x force field;
conformations with strain energy 4 kcal/mol or more above the lowest energy
conformation were discarded. This final database was screened using the 4-point SERT
S2 pharmacophore. “Hit” compounds acceptable to the pharmacophore filter were further
screened to ensure the presence of halogens and a molecular weight < 350 daltons,
features common to most of the known antidepressants. These steps yielded a pool of
4,097 hit compounds. Three hSERT docking iterations were performed with this pool of
structures. Affinity scores < -6.0 kcal/mol plus visual inspection was used to condense the
pool to 68 candidate ligands (Figure 2.8). Of these, 10 of the top-ranked 15 compounds
[(coded “SM-1” through “SM-15”), Figure 2.9] were procured from various sources and
pharmacologically tested.
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Wash, Lipinski, toxic

S2 Ph4

M.W < 350

Halogens

Dock
68 Hits
Figure 2.8. Different sequential filters used in structure-based virtual screening of
SERT.
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Figure 2.9. Chemical structures of first batch of hits identified.
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2.2.2 Experimental Methods
The experimental (pharmacological assays) were performed by Ms. Laura M.
Geffert from Dr. Christopher K. Surratt lab from Mylan School of Pharmacy, Duquesne
University.

2.2.2.1 In vitro VS Compound Binding Screen.
Compounds identified from the virtual screen were purchased and dissolved in
100% DMSO to a concentration of 10 mM. Initial one-point competition binding assays
0.1 nM of the
radiolabeled cocaine analog [125I]-RTI-55, a radioligand with high affinity at all three
MATs.

Stably transfected HEK293-hSERT membranes or N2A-hDAT or HEK293-

hNET whole cells were employed for all binding assays.

Non-specific binding was

hDAT or hNET assays, respectively. Screening results were analyzed with one-way
ANOVA (P < 0.05) with a post-hoc Dunnett's Multiple Comparison Test.

2.2.2.2 hSERT Membrane Binding Assay
hSERT binding affinities were obtained by displacement of [ 125I]-RTI-55 in
membrane binding assays. Membrane was prepared from stable hSERT-HEK cells grown
at 37˚C in a 5% CO2 environment on 150 х 25 mm plates. At 95% confluence (3 days of
growth), cells were washed twice with 10 mL cold phosphate-buffered saline (DPBS).
An additional 10 mL of DPBS was added and cells were harvested by scraping and
transferred to cold centrifuge tubes (15 mL), followed by centrifuging for 10 min at low
67

speed (700 x g). After removal of the supernatant, the cell pellet was resuspended in 500
uL cold TE buffer (50 mM Tris, 1 mM EDTA, pH 7.5). Following centrifuging for 30
min at 100,000 x g at 4˚C, the supernatant was discarded and the pellet was frozen for
later use or resuspended in ice-cold binding buffer (50 mM Tris, pH 7.5, 100 mM NaCl).
Each sample was analyzed for protein content using the Bradford protein assay. For
competition binding, membrane was incubated with [125I]-RTI-55 (0.1 nM concentration)
and increasing concentrations of cold competitor (1 nM to 1 mM), or 10 μM paroxetine to
measure non-specific binding.

Reactions were carried out in 12 х 75 mm borosilicate

glass tubes with gentle shaking at room temperature for 1 hour and terminated by rapid
filtration through GF/B filters (Schleicher and Schuell, Keene, NH) presoaked in 0.5%
polyethylenimine solution (v/v). Filters were washed twice with 5 mL cold 50 mM Tris
buffer and transferred to vials. Radioactivity was determined using a Beckman gamma
counter. For saturation binding assays, data were analyzed with GraphPad Prism 5.0
software. IC50 values were generated and converted to Ki values using the Cheng-Prusoff
equation (Ki = IC50/ (1+ ([RTI-55]/Kd RTI-55)).70

2.2.2.3 hDAT and hNET Whole Cell Binding Assays.
Whole-cell competition binding assays were performed for hDAT and hNET
using stable hDAT-N2A or hNET-HEK293 cell lines, respectively, grown at 37˚C in a 5%
CO2 environment. Cell monolayers were grown in 24-well plates to >90% confluence.
Cells were washed twice with 1 mL of KRH buffer (25 mM HEPES, pH 7.3, 125 mM
NaCl, 4.8 mM KCl, 1.3 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 5.6 mM glucose)
supplemented with 50 mM ascorbic acid (KRH/AA). Cells were incubated for 15 minutes
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with 1 nM [125I]-RTI-55 supplemented with tropolone (total volume of 500 uL) along with

(hNET). Following incubation, cells were washed twice with 1 mL KRH/AA buffer, then
treated with 1 mL 1% SDS with gentle shaking at room temperature for 1 hour. Cell
lysates were transferred into vials.

Radioactivity was determined using a Beckman

gamma counter and analyzed using GraphPad Prism 5.0 as described above.

2.2.2.4 Serotonin Uptake Inhibition Screen.
One-point competition binding assays were performed using stably transfected
HEK293-hSERT whole cells grown to >90% confluence on 24-well plates. Cells were

followed by addition of 10 nM [3H]-serotonin. After an additional 5 min, cells were
washed twice, then treated with 1% SDS and shaken for 1 hr. Lysates were transferred to
5 mL scintillation fluid and radioactivity was detected using a Beckman liquid scintillation
counter. Nonclomipramine.
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2.3 Results and Discussion
2.3.1 Model Construction and Refinement
Four discrete amino acid sequence alignments with LeuT were generated that
primarily differed in the loop regions.

Manual refinement of the alignments was

conducted to remove gaps within the TM regions. Rotamers of the residue side chains
lining the hSERT halogen-binding pocket were selected based on their ability to form a
sub-pocket, as these residues have been reported to be important for binding of certain
SSRIs.21 A total of 80 SERT homology models were built using Discovery Studio (DS)
2.5.1. Five models from each alignment (20 models total) having the lowest DOPE score
were chosen for further evaluation. The models were also deposited into the PDB
evaluation server and assessed with respect to stereochemical quality.55 The plots
generated by the server were evaluated for unusual phi-psi angles, bond lengths, bond
angles and van der Waals contacts (Figure 2.10). Two models from each alignment were
selected for further evaluation, specifically their fitness in a 3D environment assessed by
Profiles-3D. This DS module assesses the protein’s tertiary structure compatibility with
its sequence. Finally, spatial overlap of the model and template polypeptide backbone
atoms was examined to check the integrity of the model's TM domains and the volume of
its binding pocket. On this basis, "Model 1" was chosen for further studies.

70

PROCHECK

Ramachandran Plot
new-entry

180

ARG 312

B

135 b

~b

b

~b
~l

90

l

Psi (degrees)

45

L

a
A

0

~a

-45
-90VAL 379
-135

PHE 302

~b

~p

b

-180

p

-135

-90

-45

0
45
Phi (degrees)

~b

90

135

180

Plot statistics
Residues in most favoured regions [A,B,L]
Residues in additional allowed regions [a,b,l,p]
Residues in generously allowed regions [~a,~b,~l,~p]
Residues in disallowed regions
Number of non-glycine and non-proline residues
Number of end-residues (excl. Gly and Pro)
Number of glycine residues (shown as triangles)
Number of proline residues
Total number of residues

435
25
1
2
---463

94.0%
5.4%
0.2%
0.4%
-----100.0%

2
41
21
---527

Based on an analysis of 118 structures of resolution of at least 2.0 Angstroms
and R-factor no greater than 20%, a good quality model would be expected
to have over 90% in the most favoured regions.

new-entry_01.ps

Figure 2.10. Ramachandran plot analysis of the stereo chemical parameters of model
1. Residues Arg 312 (EL 3) and Val 379 (TM 7) were the outliers and are far from the S2
binding pocket.
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2.3.2 Docking and Pharmacophore Feature Generation
The MOE alpha site finder was used to identify possible ligand sites in Model 1.
A site exposed to the extracellular space was chosen based on evidence for inhibitors
binding in this vestibule.21 The combination of proxy triangle as the placement method
and force field refinement with an affinity scoring function yielded MOE docking poses of
leucine into LeuT with an RMSD of 0.31 Å. The same combination was employed to
dock the 16 structurally diverse antidepressants that possess a large range of SERT
binding affinities (0.1 nM - 9100 nM). It is acknowledged that certain SSRI ligands used
in the docking have been reported to access the interior S1 substrate pocket
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; however,

the VS pocket employed in this study contained elements of the vestibular (S2 substrate)
pocket and the halogen-binding pocket (HBP) (Figure 2.11). The latter pocket is defined
in part by hSERT residues Leu-99 (TM 1), Trp-103 (TM 1) and Ile-179 (TM 3). The
ligand-accessible region of the HBP (green cloud) is adjacent to that of the S2 pocket
(orange cloud); the HBP appears to be important for recognition of halogen-containing
inhibitors. Poses in which the halogen atom of the ligand was directed toward this pocket
were thus favored.
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Figure 2.11. Ligand-accessible regions of SERT substrate and inhibitor binding
pockets. Regions available to ligands in the S1 (blue), S2 (orange) and HBP (green)
pockets are displayed as surfaces. The pocket employed for virtual screening combined
the S2 and HBP. Residues defining each pocket are displayed as sticks (atomtype color).
For clarity, the TM1 (red), TM3 (orange), TM6 (green), TM8 (cyan) and EL4 (pink)
helices are highlighted.
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2.3.3 Development of 4-point SERT S2 Pharmacophore
Overlaying the highest-ranked poses of different antidepressants a “common
interaction pattern” was generated. Residues identified as common interaction points were
then chosen to develop a 3D pharmacophore. Pharmacophore feature F1 of radius 1 Å was
created midway between Arg-104 (TM 1) and Glu-493 (TM 10) to capture possible ionic
or H-bond interactions, particularly with protonated ligand nitrogen atoms.

Previous

reports of SERT-based pharmacophore models indicated the importance of a positively
charged nitrogen atom.72, 73 Feature F2 (radius 1 Å) was created in the vicinity of Lys-490
(TM 10) to capture possible H-bond interactions. The lysine side chain is among the more
flexible of the naturally occurring amino acids; 78 rotamers were possible for Lys-490.
The rotamer oriented toward the vestibular pocket, analogous to Asp-401 in LeuT, was
chosen to capture possible interactions with ligands. Asp-401 is reported to interact with
different antidepressants in LeuT crystal structures21; thus, Lys-490 would be expected to
play a similar role in hSERT. Feature F3 (radius 1 Å) was created to capture H-bond or
cation-π interactions with Tyr-107 (TM 1). Residues 104-106 of hSERT TM 1b are
analogous to LeuT residues 30-32, although hSERT Tyr-107 and LeuT Val-33 differ
substantially regarding the nature of potential ligand interactions. Feature F4 (radius 1.5
Å) in the HBP was designed for hydrophobic interactions believed to be important in
recognizing SSRIs.

Residues lining the pocket are conserved between hSERT and

LeuT.21 Substitution of the hSERT TM 3 residue Ile-179 (Ile-111 in LeuT) with alanine,
phenylalanine or aspartic acid increased SSRI substrate uptake inhibition potency by 7 –
1080 fold.21 The TM 1 mutations Ala77Gly in hNET and Ala81Gly in hDAT were
observed to improve SSRI affinity, suggesting a negative influence of the methyl side
74

chain of alanine on SSRI binding. Finally, an exclusion volume was added to make the
pharmacophore more stringent and selective (Figure 2.12).

Figure 2.12. Four-point pharmacophore for SERT S2 pocket displayed along with
excluded volume. The pharmacophore employed for VS was comprised of features
(colored spheres). F1: Donor/acceptor (red). F2: Acceptor (pink). F3: Cation/acceptor
(blue). F4: Hydrophobic / π ring (green) and excluded volume (grey).
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2.3.4 Virtual Screening and Pharmacological Testing
Approximately one million members of the ZINC small molecule structural library
database68 were screened with the 4-point S2 SERT pharmacophore for possible "hit"
compounds. A total of 4097 molecules were acceptable to the pharmacophore filter.
Docking of this subset into the SERT model followed by monitoring of affinity dG scores
with visual inspection of the resulting poses yielded 68 preferred compounds. Due to lack
of availability, only ten of the top 15 compounds (labeled SM-1 to SM-15) were initially
tested for hSERT, hDAT or hNET affinity in single point in vitro binding assays. Two
compounds, SM-10 and SM[125I]-RTI-55 from hSERT membranes, indicating measurable hSERT affinity. At the
same final concentration, these two compounds did not displace the radioligand at hDAT
or hNET cells. (Figure 2.13) SM-10 and SM-11 were further characterized at hSERT
HEK293 membranes in competition assays to obtain Ki values for inhibition of [125I]-RTI55 binding. The binding affinity values for SM-10 and SM-11 towards hSERT are 38 ± 17
μM and 17 ± 7 μM respectively with SM-11 binding stronger than SM-10 (Figure 2.14).
SM-10 and SM-11 were also screened for the ability to inhibit uptake of [ 3H]-serotonin by
intact hSERT HEK293 cells. Because no inhibition of [3H]-serotonin uptake was detected
50

values

were not obtained (Figure 2.15).
But surprisingly SM-14 (Figure 2.16) was found to be DAT selective by
displacing [125I]-RTI-55 at hDAT cells alone. A DAT binding affinity Ki value of 15.6 ±
2.4 μM (mean ± s.e.m.) and a dopamine uptake inhibition potency IC50 value of 10.5 ± 4.6
μM were observed. (Figure 2.17 and Figure 2.18) Given the high sequence similarity (~
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50%, as calculated with BLAST) among the three-hMATs, finding a specific inhibitor that
targets a single transporter is a challenging task.

VS is more precarious with the

additional inhibitor binding pocket uncertainty associated with a homology model built
using a template sharing < 30% sequence identity. Because of this handicap, and because
the goal of the study was to identify SERT ligands of novel structural scaffold, a very high
concentration of VS hit compound relative to the SERT ligand radiotracer (100,000-fold)
was employed in the pharmacologic screen. The observation that most of the VS hits
showed no ability to displace the radioligand at the SERT-HEK cells confirms that the
huge molar ratio of VS compounds: radiotracer was itself insufficient for decreasing
radiotracer binding (i.e., some SERT affinity is required to register a response in this
assay).
The two VS hits pharmacologically verified as SERT ligands displayed
micromolar Ki values. These binding affinities are very low compared to the nanomolar
or better SERT affinities of certain SSRI therapeutics. Inhibition of serotonin uptake was

uptake inhibition potency is often lower than binding affinity for a given MAT inhibitor,
possibly due to differences in MAT conformational or population requirements for the two
processes.74, 75

-10 or SM-11 concentration employed may be above the

threshold for detecting SERT ligand binding but below the threshold for detecting
serotonin uptake inhibition.
Micromolar affinities for VS hit compounds are common when homology models
are employed.76-83 From this research team, the first reported VS effort based on a DAT
homology model yielded a hit compound (MI-4) with low micromolar DAT affinity and
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slightly better (high nanomolar) SERT affinity. Without modification, this compound
displayed antipsychostimulant and antidepressant properties (Ref. 43 and unpublished
data). The same VS effort using a DAT model yielded a hit compound (MI-17) with a
SERT Ki value of 284 nM. An MI-17 analog designed to increase SERT selectivity
resulted in a compound with a SERT Ki value of 37 nM, and SERT: DAT and SERT:
NET selectivity ratios of 50 and over 200 respectively.45 Thus, VS hit compounds with
micromolar affinities appear to be useful as lead compounds for medication development.
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Figure 2.13. VS hit compound in vitro MAT binding screen.
final concentration were tested for the ability to inhibit [ 125I]-RTI-55 binding at hSERT
HEK293 cells (top panel), hDAT N2A neuroblastoma cells (middle panel), or hNET
HEK293 cells (bottom panel). Non-specific binding was assessed by the presence of 10
respectively. Data represent n=3 independent experiments performed in duplicate. Data
are presented as the mean ± s.e.m. and were analyzed by one-way ANOVA with
Dunnett’s multiple comparison post-hoc test. *P < 0.05 vs. total binding for that assay.
***P < 0.0001 vs. total binding for that assay. (Provided by Ms. Laura M. Geffert)
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Figure 2.14.
Saturation binding of VS hit compounds. SM-10 (closed circles) and
SM-11 (open circles) at hSERT HEK293 cells. Binding affinity K i values were
determined via displacement of [125I]-RTI-55. n=3 experiments. (Provided by Ms. Laura
M. Geffert)
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Figure 2.15. VS hit compound in vitro serotonin uptake inhibition screen.
3
H]serotonin uptake by hSERT HEK293 cells. Non-specific radioligand uptake was assessed
experiments performed in duplicate. Data are presented as the mean ± s.e.m. and were
analyzed by one-way ANOVA with Dunnett’s multiple comparison post-hoc test. *P <
0.05 vs. total uptake for that assay. **P < 0.001 vs. total uptake for that assay. (Provided
by Ms. Laura M. Geffert)
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Figure 2.16. Structures of hits identified through virtual screening SM-10, SM-11
and SM-14.

82

Figure 2.17. Saturation binding of VS hit compounds SM-14 at hDAT N2A cells.
Binding affinity Ki values were determined via displacement of [ 125I]-RTI-55. (n=3
experiments). (Provided by Ms. Laura M. Geffert)
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Figure 2.18. Dopamine uptake inhibition potency of VS hit compound SM-14 at
hDAT N2A cells. Uptake inhibition Binding affinity Ki values were determined via
displacement of [125I]-RTI-55. (n=3 experiments). (Provided by Ms. Laura M. Geffert)
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2.4 Structural Novelty of SM Hit Compounds
Given their structural flexibility, SM-10, SM-11 and SM-14 greatly differ from the
SSRIs and TCAs that were employed to develop the pharmacophore (Figure 2.16). The
Tanimoto similarity coefficient was calculated for the three hits to identify the
dissimilarity compared to the known inhibitors (SSRI, TCA). A coefficient of less than 0.6
was calculated, which signify the structural novelty of these hits. More specifically, the
SSRIs and TCAs currently being used contain either rigid or fused rings when compared
to the flexible SM hits. This flexibility would provide the additional advantage of reaching
the higher affinity substrate pocket. The similarities between the SSRIs and SM hits are
the presence of a charged amine group and halogen atoms, which are required for SERT
inhibition. In addition, the flexibility of these molecules with well separated rings presents
additional attach points to optimize SERT affinity and can be developed as multi site
drugs.

2.4 Conclusion
To our knowledge this is the first study to identify novel SERT-selective reuptake
inhibitors through VS performed with an hSERT homology model. Conventional drug
development usually involves creation of analogs of established ligands for a given
receptor. In contrast, the VS approach affords the possibility of discovering ligands with
very different scaffolds, ligands that in all likelihood would never be otherwise identified
for that receptor. In the case of the SERT, inhibitors of novel scaffold provide new
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opportunities for development of rationally designed multi-site drugs (e.g., SERT/5HT2A/5-HT3 blockers) that address the therapeutic goal while mitigating the adverse
effects associated with the SSRI drug class. It is anticipated that the two SM compounds
described herein should serve as lead compounds toward the treatment of depression,
anxiety, and other serotonin-related disorders.

2.5 Future Directions
Lead optimization is the next step after lead identification in drug discovery. In
this study two novel scaffolds selective to SERT were identified. Of the two leads, SM-10
has a better affinity but it has three stereo centers. Purchasing the different possible
stereoisomers and testing them seems to be the next logical step. As the leads were low
affinity binders, hit-to-lead optimization has to be performed to identify higher affinity
analogues. Even though these leads were identified through S2 pocket virtual screening,
the location of the binding pocket and the relative orientation of the ligand in the
transporter are speculative. As these novel ligands are flexible an assumption can be made
as part of these ligands may reach S1 pocket with rest of the molecule docked into S2. So
the studies that identify the binding orientation and modification of the scaffold extend
this study.
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Chapter 3.
ELUCIDATION OF BINDING PROFILE SIMILARITIES
AMONG STRUCTURALLY DIVERSE INHIBITORS OF
DOPAMINE TRANSPORTER

3.1 Introduction
Dopamine transporter (DAT), norepinephrine transporter (NET) and serotonin
transporter (SERT) belong to the family of monoamine neurotransmitters (MATs). They
play an important role in maintaining the neurotransmitter levels that control mood,
hunger etc.1 Imbalance in the levels of neurotransmitters is the primary cause for several
psychological disorders like addiction, depression etc.

Various experimental studies

performed imply that DAT is primarily responsible, for the reward/reinforcing properties
associated with psychostimulant substances like cocaine and amphetamines.2-5
Very little is known about how these addictive substances interact with DAT and
block dopamine reuptake. Structurally, diverse inhibitors interact with DAT by binding to
different non-overlapping binding sites.6,

7

To identify the exact location of binding

pocket, photoaffinity probes of dissimilar scaffolds were developed. In the presence of
ultra violet light, they form a covalent bond with the amino acid residues in DAT, which is
then identified by mass spectrometric studies (Figure 3.1).
Analogues of the tropane-based

8-17

with very flexible piperidine18 and piperazine

analogues19-24 were developed and used as photo probes (Figure 3.2) with less focus on
non-tropane based analogues.25-27 Photoaffinity probes based on the tropane analogues
96

covalently bond to residues far from the binding pocket and may not provide the precise
location. So, the probes with photoaffinity groups substituted directly on the inhibitor
were developed to provide a much better picture.

97

Target Protein

Photoactive group

Photoaffinity ligand

Irradiation with UV light

Binding site

Fragmentation

F
L
L
LY

S

A

K
L
Figure 3.1. Schematic representation
of the photoaffinity labeling of a protein. The
L
target protein (DAT) is represented by a blue rectangle, photoaffinity ligand (red triangle)
and a photoactive group (green star). Upon irradiation by ultra violet light, photoactive
group on photoaffinity ligand forms a covalent bond with DAT. The protein is lysed and
the polypeptide fragments are analyzed by mass spectrometry to identify the location of
covalent linkage.
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Figure 3.2. Structures of tropane- and piperazine-based DAT photoaffinity ligands.
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3.2 Methods
Numerous analogues synthesized in the scheme towards final photoprobe were
also included to better understand the structure activity relationship (interaction pattern)
with DAT. The 3D-coordinates of parent compounds and analogues of the three diverse
scaffolds (groups) were drawn in molecular operating environment (MOE). 28 Partial
charges and hydrogen atoms were added to all ligands using Merck Molecular Force Field
94X (MMFF94x).29,

30

The geometry of these ligands was then refined using energy

minimization module with a convergence criteria of 0.01 kcal/mol in MOE.
A DAT homology model previously generated was employed to dock these
compounds.31 As the binding pocket of these inhibitors was unknown and only
extracellular pocket (S2) was accessible to all the analogues, the focus of the study
involved docking these ligands into the S2 pocket. Moreover, S2 site was proposed as a
staging area for inhibitors before sliding further into the S1 pocket. 32
The biomoleular force field, assisted model building with energy refinement
(AMBER 99) was used to add partial charges and hydrogen atoms to the homology model
of DAT.33, 34 The previously proposed S2 pocket was chosen as the site to dock ligands,
and a sphere of 8 Å radius was constructed in this pocket.
Three different docking runs were performed for each group, which included the
parent compound and their analogues. The separate databases generated for each group
were then merged together into a single database. The compound database was then
provided as an input for the protein ligand interaction fingerprint (PLIF) panel in MOE.
The PLIF tool generates a population histogram that represents the protein-ligand
interaction pattern. PLIF is a computational tool to encapsulate the interaction pattern by
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generating fingerprints of docked poses. A fingerprint is a sequence of binary bit strings
that associates different structural features of a molecule, and is a commonly employed
method in various ligand-based approaches.35-37

3.3 Results and Discussion
All analogs towards the synthesis of final photoactive probes for dissimilar
scaffolds were also included in the study to understand the structure-activity relationship
(SAR).25-27 An assumption was made that all these diverse inhibitors bind in the same
pocket, and were docked into the S2 pocket of DAT.
The homology model of DAT used in this study was constructed using the
occluded conformation of LeuT (pdb id:2a65) with the primary substrate pocket (S1)
completely blocked by the extracellular gates. 38 As the S2 pocket is large and exposed
towards the extracellular space, a sphere was created to constraint the docking poses in
DAT. Docking runs were performed to generate various docked poses in MOE.
The fingerprints were then generated for each docked pose using PLIF analysis. It
considers

six

different

non-bonded

interactions

[side

chain

hydrogen

bonds

(donor/acceptor), back bone hydrogen bonds (donor/acceptor), ionic interactions and
surface contacts] into account to generate a fingerprint for each pose. Clustering of these
fingerprints was then performed to generate a histogram that showed the interaction
pattern of each docked pose.
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Bupropion: A number of bupropion analogues with varying substitutions on aromatic
ring were synthesized (see Figure 3.3).39,

40

It was perceived that halogen substituted

analogues had higher DAT affinity, which implies that bulky substitutions were well
tolerated. It was also noticed that the parent compound bupropion (441 nM) is seven fold
stronger than its photoprobe analog, SADU-3-72 (3071 nM) in DAT N2A neuroblastoma
cells.40 The fingerprint analysis (Figure 3.5) identified that the terminal amino group
interacts with Asp 312 (TM6) and the azide group forms an ionic bond with Asp 475
(TM10), which wasn’t detected for bupropion (Figure 3.4). A clear trend of increased
interaction profile with Asp 475 was identified (Figure 3.5) for the photoprobe. The trend
suggested that the highly reactive nitrene generated upon UV light would covalently link
to Asp 475.

Figure 3.3. Structures of bupropion and its photoactive probe.
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Figure 3.4. Two-dimensional docking interaction plot of the bupropion photoprobe.
The hydrophobic residues (green spheres) and hydrophilic residues (pink spheres) in the
pocket are displayed. The azide group (N3) interacts with Asp 475 demonstrating the
possibility of covalent bond formation with the residue.
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Figure 3.5. PLIF panel of bupropion and photoprobe docked poses. Each docked
pose is indicated by a row, black rectangles in each row represent the interacting residues.
A residue may interact with a docked pose in six different ways, with more than one
rectangle observed for a single residue. The red bracket represents bupropion poses and
the blue bracket indicates the photoprobe docked poses. The panel clearly shows the
increased interaction profile of photoprobe with Asp 475.
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Pyrovalerone: The differences between the bupropion and pyrovalerone were very
minimal with a great difference in affinity. Bupropion consists a secondary nitrogen,
where as the pyrovalerone contains a tertiary nitrogen. The other minor difference was the
pyrovalerone had a longer alkyl chain (n-propyl group) compared to the shorter methyl
chain in bupropion. The larger pyrovalerone is fifty fold stronger than bupropion in DAT.
Substitution on the aromatic ring of pyrovalerone was also better tolerated as in
bupropion without any appreciable loss of affinity (Figure 3.6). The pyrovalerone
photoprobe was designed by substituting the 4’-methyl group with photoreactive azide (N3) and iodine (I) at the 3’ position. The bulky substitutions on the final photoprobe result
in ten-fold less affinity compared to pyrovalerone.

Aromatic

3

Compound

H-WIN binding inhibition

substituent

Ki (nM)

R1 (3’)

R2 (4’)

H

Me

Pyrovalerone

8±2

I

N3

Photoprobe

78 ± 18

H

NH2

Amino pyrovalerone

5±1

I

NH2

Amino, iodo-pyrovalerone

28 ± 8

Figure 3.6. DAT binding affinity of pyrovalerone and its analogues. (Provided by Dr.
David J. Lapinsky)
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The five-fold affinity difference between the amino substituted pyrovalerone and
the dual substituted pyrovalerone suggest the detrimental effect of bulky iodine group.
Similar to the bupropion photoprobe, the pyrovalerone photoprobe also showed an
increased interaction pattern with Asp 475. As the scaffolds of bupropion and
pyrovalerone were similar, the ionic interaction with Asp 475 is no strange observation. It
is proposed that the photoprobes based on these scaffolds would form a covalent bond
with the charged residue.

Methylphenidate: It is structurally larger and diverse compared to bupropion and
pyrovalerone. The iodo and azido-substitution on the same ring motif, may lead to a low
efficient photoprobe for this scaffold, and so methylphenidate was hybridized to better
accommodate the iodo and azido groups on separate rings without a loss in affinity
(Figure 3.7). The fingerprint analysis of methylphenidate showed no H-bonding pattern
due to the lack of H-bond groups. The PLIF analysis identified that the methylphenidate
and iodo-substituted analogs interact with Thr 472 and Asp 475 residues.
Much like the other two scaffolds, the halogen substitution on the aromatic ring
was well tolerated on this scaffold. The para-azido substitution on the hybrid analogues
had better affinity compared to the ortho and meta-substituted analogs. The azido group
substituted on the hybrid analogues formed a H-bond with Ser 308 (TM6) and an ionic
interaction with Asp 312 (TM6). Based on the PLIF pattern identified, it is speculated that
the nitrene generated will covalently link to either one of these residues.
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Substitution Compound

H-WIN binding inhibition
Ki (nM)

H

Methylphenidate
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Figure 3.7. Structures and activity profile of methylphenidate analogues. (Provided by
Dr. David J. Lapinsky)
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3.4 Conclusion
Numerous DAT photoaffinity probes with diverse scaffolds were developed for
identifying the inhibitor-binding pocket in DAT. They include tropane-based and
piperazine-based analogues with a very long flexible linker, separating the azide group
and the pharmacophore. These scaffolds have an inherent problem with the covalent bond
forming far from the binding pocket. This defeats the purpose of the scaffolds, and so the
search for probes with the photoactive groups directly on the scaffold or with a short tether
would help in better identification of the binding pocket of DAT inhibitors.
The PLIF analysis of bupropion photoprobe showed the increased possibility of
covalent bond formation with the Asp 475. It was noticed that the pyrovalerone
photoprobe also showed a similar interaction pattern as the bupropion photoprobe. This is
no strange observation being the two scaffolds were very similar. The methylphenidate
and its hybrid analogs were bigger compared to the probes of other scaffolds and so a
difference in interaction pattern was observed. It was identified that Ser 308 and Asp 312
residues were closer to the azido group, and the methylphenidate probe may form a
covalent bond with either one of these residues.
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Chapter 4.
RATIONAL

DESIGN

OF

NOVEL

ORTHO-AMIDO

DIPHENYLAMINES AS SELECTIVE MEK5 INHIBITORS
THROUGH DEVELOPMENT OF A MEK5 HOMOLOGY
MODEL

4.1 Introduction
Kinases are important cellular proteins that catalyze the transfer of a terminal
phosphoryl group from adenosine triphosphate (ATP) to specific hydroxyl groups of
serine, threonine or tyrosine residues. 1 Mutations of these residues to acidic counterparts
(often called DD, EE, or DE mutants) render kinases with significantly elevated activity,
commonly observed in several cancers. Mitogen activated protein kinase [(MAPKs), also
called as extracellular signal regulated kinases (ERKs)] belong to the family of Ser/Thr
kinases. The MAPK pathway consists of a series of numerous interconnected signal
transduction pathways that transfer extracellular responses into the cell nucleus, to control
several cellular responses such as embryogenesis, proliferation and cell death (Figure
4.1).2-7
The human genome encodes seven MEK enzymes that regulate the activity of
MAP kinase pathways. Aside from the highly similar MEK1/MEK2, other members of
the family consist of MEK3, MEK4, MEK5, MEK6 and MEK7. Of all these proteins,
MEK5 present as an attractive target for therapeutic intervention, because of the detection
of elevated levels in squamous cell carcinoma8, prostrate9 and breast cancers.10
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Drug resistance to the approved anticancer agents like imatinib, gefitinib and
erlotinib has become a growing concern.11 To address this, another interesting concept is
in the developmental stages, where inhibitors with more specificity and minimal side
effects are being developed. The inhibitors attack the targets downstream ensuring that
only certain functions are eliminated in the signaling cascade. These inhibitors are called
non-classical kinase inhibitors, where they occupy a pocket allosteric to the substrate ATP
pocket, there by becoming effective against only a selected panel of kinases.12 Two studies
of MEK5 inhibitors were reported. One study involves the development of oxindole
derivatives13 as classical kinase inhibitors (ATP-competitive); where as the other study14
reported the development of non-classical (allosteric) inhibitors. It is assumed that the
allosteric inhibitor binding induces a conformational change in the unphosphorylated
kinase (MEK) by locking it into a catalytically inactive conformation.3
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Figure 4.1. The signaling cascade of MEK family.14 (Adapted with permission from
Flaherty et al. BMCL 2010,20, 2892-2896.)
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4.2 Methods
4.2.1 Retrieval of sequence
Three different isoforms- A, B and C of human MEK5 were identified (Figure
4.2).15-17 The splice variant B (referred to as MEK5 β further) is the canonical sequence;
and longer (448 residues) than the remaining isoforms, expressed primarily in cytosol. The
isoforms, “A” and “C” were comparatively shorter, with isoform A being the shortest. The
fasta sequence of human MEK5 β (accession number Q13163) was downloaded from the
Uniprot database18.

MEK5 β has a conserved motif “S311xxxT315” which is the

phosphorylation, and activation motif.

Mutagenesis of Ser 311 and Thr 315 to Asp

residue constitutively activates MEK5, whose levels are observed to be significantly
elevated in different types of cancer. By mutating these two residues to aspartate in the
downloaded primary sequence a constitutively active mutant was generated (Figure
4.3).16
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ISOFORM B
>sp|Q13163|MP2K5_HUMAN Dual specificity mitogen-activated protein kinase kinase 5
OS=Homo sapiens GN=MAP2K5 PE=1 SV=2
MLWLALGPFPAMENQVLVIRIKIPNSGAVDWTVHSGPQLLFRDVLDVIGQVLPEA
TTTAFEYEDEDGDRITVRSDEEMKAMLSYYYSTVMEQQVNGQLIEPLQIFPRACK
PPGERNIHGLKVNTRAGPSQHSSPAVSDSLPSNSLKKSSAELKKILANGQMNEQDI
RYRDTLGHGNGGTVYKAYHVPSGKILAVKVILLDITLELQKQIMSELEILYKCDSS
YIIGFYGAFFVENRISICTEFMDGGSLDVYRKMPEHVLGRIAVAVVKGLTYLWSL
KILHRDVKPSNMLVNTRGQVKLCDFGVSTQLVNSIAKTYVGTNAYMAPERISGE
QYGIHSDVWSLGISFMELALGRFPYPQIQKNQGSLMPLQLLQCIVDEDSPVLPVG
EFSEPFVHFITQCMRKQPKERPAPEELMGHPFIVQFNDGNAAVVSMWVCRALEER
RSQQGPP------

Figure 4.2. Multiple sequence alignment of different isoforms of human MEK5.
Consensus of residues among the three isoforms displayed, stars represent identical
residues, dots represent dissimilar residues, and gaps shown by dashes.
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Isoform B (wild type)
MLWLALGPFPAMENQVLVIRIKIPNSGAVDWTVHSGPQLLFRDVLDVIGQVLPEA
TTTAFEYEDEDGDRITVRSDEEMKAMLSYYYSTVMEQQVNGQLIEPLQIFPRACK
PPGERNIHGLKVNTRAGPSQHSSPAVSDSLPSNSLKKSSAELKKILANGQMNEQDI
RYRDTLGHGNGGTVYKAYHVPSGKILAVKVILLDITLELQKQIMSELEILYKCDSS
YIIGFYGAFFVENRISICTEFMDGGSLDVYRKMPEHVLGRIAVAVVKGLTYLWSL
KILHRDVKPSNMLVNTRGQVKLCDFGVSTQLVNSIAKTYVGTNAYMAPERISGE
QYGIHSDVWSLGISFMELALGRFPYPQIQKNQGSLMPLQLLQCIVDEDSPVLPVGE
FSEPFVHFITQCMRKQPKERPAPEELMGHPFIVQFNDGNAAVVSMWVCRALEERR
SQQGPP
Isoform B DD (constitutively active mutant)
MLWLALGPFPAMENQVLVIRIKIPNSGAVDWTVHSGPQLLFRDVLDVIGQVLPEA
TTTAFEYEDEDGDRITVRSDEEMKAMLSYYYSTVMEQQVNGQLIEPLQIFPRACK
PPGERNIHGLKVNTRAGPSQHSSPAVSDSLPSNSLKKSSAELKKILANGQMNEQDI
RYRDTLGHGNGGTVYKAYHVPSGKILAVKVILLDITLELQKQIMSELEILYKCDSS
YIIGFYGAFFVENRISICTEFMDGGSLDVYRKMPEHVLGRIAVAVVKGLTYLWSL
KILHRDVKPSNMLVNTRGQVKLCDFGVSTQLVNDIAKDYVGTNAYMAPERISG
EQYGIHSDVWSLGISFMELALGRFPYPQIQKNQGSLMPLQLLQCIVDEDSPVLPVG
EFSEPFVHFITQCMRKQPKERPAPEELMGHPFIVQFNDGNAAVVSMWVCRALEER
RSQQGPP

Figure 4.3. Differences between the wild type MEK5 isoform β and its constitutively
active mutant. The dissimilarities are indicated with pink colored residues.
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4.2.2 Search for the template
Seven members have been identified that belong to the MEK family. 14

The

phylogenetic analysis reveals that MEK5 is more closely related to MEK1 with 48%
sequence identity (Figure 4.4). A search for the MEK1 crystal structures identified 14
different crystal structures in PDB (accessed Dec 2010). 19 The protein with pdb id (3eqc)
was selected as the template and the coordinates were downloaded and loaded into
Discovery studio 2.5.1. (DS)20
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Figure 4.4. Phylogenetic analysis of the members of MEK family. MEK1, MEK2 and
MEK5 belong to a group, where as the rest of the family members are more evolutionarily
related to each other.
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4.2.3 Protein check of the template
The template was checked for missing residues/atoms (protein quality) using
protein reports and utilities module in DS. The report identified missing residues at both
the polypeptide terminals, gaps between residues Ala 220 and Val 224, gaps between Cys
277 and Pro 307 in the template. As the missing residues at both the terminals and the
residues between Cys 277 and Pro 307 in the alpha helix domain were far from the
binding pocket, no effort was taken to build the 3D coordinates. The residues between
Ala 220 and Val 224 in the activation loop were built and refined by the loop refinement
protocol in DS. Of the five residues modeled, only Phe 223 had two different plausible
conformations generated (Figure 4.5).

The conformation pointing into the allosteric

pocket is labeled as Phe 223_in and the one pointing towards p-loop is labeled as Phe
223_out.
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Figure 4.5. The two different conformations of Phe 223 generated in MEK1 through
loop modeling. The amino acid residue is displayed as ball and sticks. The conformation
pointing into the allosteric pocket is labeled as Phe 223_in (orange) and the conformation
pointing up towards p-loop is labeled as Phe 223_out (green).
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4.2.4 Sequence Alignment
Using default settings on the clustalW2 server, 21 the amino acid sequences of
active mutant MEK5 βDD and modified 3eqc were aligned (Figure 4.6).

The two

important motifs DFG and HRD were made sure to align between the sequence and
template.

Figure 4.6. Sequence alignment of MEK5 β DD and MEK1 used to build homology
models. Conserved residues between MEK1 (top) and MEK5 β DD (bottom) are
highlighted in yellow; similar residues highlighted in red. Secondary structure elements
are displayed on top of the sequences with helices as coils, beta-strands as blue arrows and
loops as black lines. Gaps relative to the other sequence are shown as dots. Residues are
numbered and indicated at the beginning and end of each line. Stars at the bottom identify
the phosphorylation residues: Ser 311 and Thr 315 mutated to Asp and black boxes
highlight the conserved domains HRD and DFG.
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4.2.5 MEK5 model construction
The two different templates that varied in the Phe 223 conformation were used to
construct homology models. The model building resulted in the generation of two
different MEK5 β DD models, which differed in the orientation of Tyr 316, an analogous
residue to Phe 223 in MEK1. Both the templates were used to construct homology
models, as there was no knowledge of the preferred conformation among the MEK family
and with the loop being very flexible. Ten models of MEK5 β DD were built using each
template resulting in the creation of a total of twenty models. A model was picked from
each set based on the discrete optimized protein score22 (DOPE) and 3D profile scores for
further docking calculations.

4.2.6 Docking
Various diphenyl amino analogues tested at MEK1 and MEK5 were used to
comprehend the interaction pattern of allosteric inhibitors with MEK5 (unreported). The
coordinates of these ligands were drawn using builder in molecular operating
environment23 (MOE) and partial charges, hydrogen atoms were added using Merck
molecular force field 94X (MMFF94x). 24, 25 The geometry of ligands was optimized using
energy minimization module with a convergence criteria of 0.01 kcal/mol in MOE. The
coordinates of Mg+ ion were copied from the template MEK1 to MEK5 models to mimic
the natural cellular environment. Three independent docking runs of the diphenylamine
analogues were performed at both the homology models of MEK5 β DD.
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4.3 Results and Discussion
4.3.1 Homology Modeling
MEK5 belongs to the family of Ser/Thr kinases and so the phosphorylation motif
residues, Ser 311 and Thr 315 present in the activation loop were both mutated to Asp, to
mimic the constitutively active mutant MEK5 β DD. The rotamers that mirrored the
coordinates of Ser and Thr were selected; and keeping the rest of residues fixed, the new
coordinates were energy minimized in MOE. As MEK5 is more evolutionarily related to
MEK1, the search for MEK1 in PDB resulted in identification of 14 X-ray structures.
The pdb id (3eqc) was chosen as the crystal structure was obtained at a higher
crystallographic resolution. The protein report identified missing residues in the template
with a gap between the residues Ala 220 and Val 224. The missing residues Asn 221, Ser
222 and Phe 223 present in the activation loop may play a significant role in the allosteric
inhibition and ERK phosphorylation, as they were closer to the allosteric pocket. The
other reason to construct the 3D coordinates is the uncertainty in the different
conformations adopted by Phe 223 revealed by fourteen different MEK crystal structures
(Figure 4.7).
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Figure 4.7. Superposition of the fourteen MEK1 crystal structures. The protein,
MEK1 is displayed as wires with ATP displayed as sticks (atom type color), allosteric
inhibitor is exhibited as ball and sticks (atom type color) and Mg +2 ion as brown sphere.
Different conformations adopted by Phe 223 residue present in the activation loop show
the substantial loop movement.
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The ambiguity in the Phe 223 conformation and missing residues next to the
allosteric pocket in the template led the effort to construct the 3D coordinates. The
coordinates of these residues were built using the loop refinement protocol available in
DS.

Of the three residues modeled, the protocol generated two possible different

conformations with equal probability for Phe 223, and a single optimal conformation for
rest of the residues.
The templates with different conformations of Phe 223 were selected based on a
low DOPE score.

DOPE is an atomistic based statistical potential for the model

evaluation and structure prediction. This score is viewed as a conformational energy that
measures the relative stability of one conformation with respect to others. Therefore, the
two templates with different rotamers of Phe 223 were used to construct the models of
MEK5 β DD.
By aligning the conserved motifs (HRD and DFG) followed by nonconserved
domains between MEK1 and MEK5, a sequence alignment was generated. Even though
the overall sequence identity (~40%) is less, there is a higher homology (~80%) in the
binding pockets. The sequence alignment identified Tyr 316, to be an analogous residue
to Phe 223 present in the activation loop (Figure 4.7). Even though both residues were
aromatic, Tyr 316 may form additional H-bond and cation-π interactions with allosteric
inhibitors.
Using the sequence alignment and two MEK1 templates, ten models of MEK5
active mutant were constructed for each template. So a total of ten MEK5 models with Tyr
316 pointing into the allosteric pocket and ten models with Tyr 316 pointing up towards
the p-loop were generated. Two models with favorable DOPE scores were selected from

128

each group. The Ramachandran plots (Figure 4.8) of these two models in both the groups
were analyzed to pick a final model with a least number of outliers, resulting in two final
MEK5 models with different conformations of Tyr 316.The all-atom force field, assisted
model building with energy refinement (AMBER 99) was used to add partial charges and
hydrogen atoms to MEK5 homology models. 26, 27
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Figure 4.8. Sequence alignment of activation loop of MEK1 (top) and MEK5 β DD
(bottom). Identical residues are highlighted by yellow and similar residues by red. Black
boxes represent the conserved motifs. The analogous residue to Phe 223 (MEK1) is Tyr
316 (MEK5) is represented by a blue sphere at the bottom.

130

Figure 4.9. Ramachandran plot of the final MEK5 β DD homology model. The
outliers in the model that are away from the binding pockets are represented by plus signs
with non-outliers as green and yellow spheres.
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4.3.2 Docking
A series of diphenylamines with amine side chain modification were synthesized
previously, and tested for inhibition of relative phosphorylation at ERK1/2 and ERK5
(unreported) (Table 4.1). The ability of diphenylamine analogues to block in vivo EGFinduced ERK1/2 and EKR5 phosphorylation was measured using this assay. This assay is
purely a qualitative measurement of inhibition of relative phosphorylation of ERK5
induced by mutagens
The 3D structures of diphenylamine analogues were built and refined using MOE.
The homology models of MEK5 β DD were then loaded in MOE. The magnesium ion
present in the MEK1 crystal structure was added to both MEK5 final models to mimic the
natural cellular environment. As there is a higher homology in the allosteric pockets
between MEK1 and MEK5; and PD0325901 being a diphenylamine analogue, a
reasonable assumption was made that the newly designed analogues will also bind in a
similar fashion to MEK5. So the co-crystallized MEK1inhibitor, PD0325901 was also
added to both the models to guide the docking studies. As the activation and p-loops were
very flexible, both models of MEK5 β DD were used further to dock diphenylamine
analogues.
Three independent docking runs were performed keeping the side chains of pocket
residues in 6Å relaxed and backbone atoms fixed. As the allosteric pocket is bound and
formed by mostly flexible loops, docking was modeled by allowing the side chain
flexibility. Of the seven analogues docked, iodine atom on the ligand with the shortest
side chain was found to interact electrostatically with the backbone carbonyl of Ile 225.
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The amide side chain was observed to from H-bond with Lys 195, Asp 301 and with
hydroxyl group of Tyr 316 (Figure 4.9).
The piperazine, morpholine and piperidine analogues oriented in a similar fashion
with heterocyclic rings forming hydrophobic stacking with Tyr 316. The rest of the
analogues with beta-hydroxyl side chain, and amino acid substitutions were observed to
form favorable interactions in the pocket. Even though the last three analogues were
computationally favorable, no inhibition of relative phosphorylation was observed
experimentally at both ERK1/2 and ERK 5. The reason may be due to the pocket being
hydrophobic and the analogues being hydrophilic. Careful visual inspection of all the
docked poses of analogues and scores showed that Tyr 316_in conformation was favored
over the Tyr 316_out conformation. Therefore the MEK5 homology model with Tyr
316_in conformation was chosen as the final model for further studies.
As the diphenylamine analogues were active at both MEK1 and MEK5,
and some compounds showed selectivity towards MEK5 (Table 4.1), the structures of
both proteins were superposed to identify the differences in the pockets (Figure 4.10).
Using the interaction pattern identified by diphenylamine analogues and the structural
differences between these two proteins, three different series of inhibitors were designed
(Figure 4.11). The first series was to simulate the in vivo Mg ion, the Tyr 316 series was
designed to interact with Tyr 316 residue in the activation loop and lock the protein in an
inactive conformation, where as the central ring modifications were to find the minimal
halogen substitution on rings.
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Analogue
(R)

Amide
variation

-NH2

NH2

blank

pERK1/2
relative %
phosphorylation
3.19

pERK5
relative %
phosphorylation
41.0

1-methyl
piperazine

254.0

63.0

morpholine

251.0

72.0

piperidine

233.0

82.0

β-hydroxy
ethyl
(S) serine

1.65

45.0

218.0

100.0

(R) serine

174.0

121.0

100.0

100.0

Table 4.1. Various biphenyl analogues of PD0325901 synthesized and tested for
inhibition of phosphorylation of the substrate. (Provided by Dr. Patrick T. Flaherty)
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Figure 4.10. Docking interactions of the shortest side chain diphenylamine analogue
with MEK5 β DD. Residues interacting with the ligand (sticks in atomtype color)
displayed as lines (atomtype color) and MEK5 is represented as yellow cartoon. The 2D
interaction plot shows the ligand interactions in the allosteric pocket.
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Figure 4.11. Superposition of crystal structure of 3EQC (grey) over model of MEK5
β DD (red). The allosteric ligand of 3EQC is shown as sticks. Residues differing in both
the catalytic site as well as the allosteric pocket are highlighted and colored according to
the protein chain.
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Mg ion mimetics

Tyr 316 series

Central ring modification

Figure 4.12. Different series of MEK5 inhibitors designed. Mg mimetic is to simulate
the Mg ion role, Tyr 316 series is supposed to interact and lock Tyr 316 residue present in
the activation loop; central ring modifications are to identify minimal substitution on the
ring without substantial loss of activity.
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4.4 Conclusion
MEK5 is significantly upregulated in breast and prostate cancers. A series of ATP
competitive ligands were developed for kinases, but the mutational strategy played by the
cancer downplays these inhibitors. Moreover, ATP competitive ligands were not selective
and had failed before reaching preclinical trials. The new focus of developing small
molecules for kinases is through allosteric inhibitors thereby stopping the signaling
cascade necessary for cancer cell survival. In this study, a homology model of MEK5 β
DD was developed and refined. The model was utilized to guide the rational design of
allosteric inhibitors through docking and different series of analogues were proposed to
inhibit ERK5 phosphorylation.
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Conclusions and Future Directions
Based on the results presented in this dissertation, several new research objectives
are recommended.
The usage of antidepressants in the market is limited by their side effects. New
antidepressants with reduced side activity profile are sought. Among the newer generation
is the recently approved antidepressant “Vilazodone”. It is a dual acting antidepressant
with SERT inhibitory action, and partial agonistic activity at the 5-HT1A receptor. The
physiological role of 5-HT1A receptor is to inhibit feedback mechanism that decreases
serotonin concentration in the synapse. The blockade of 5-HT1A receptor in addition to
SERT results in rapid onset of antidepressant action with less side effect profile.
From a SERT perspective, two selective novel scaffolds (SM-10, SM-11) were
identified form virtual screening. Additionally, a DAT selective compound (SM-14) was
identified, which could be developed towards treating cocaine addiction. The two SERT
selective compounds can serve as promising drug candidates for further drug
development, and rational optimization of these two hits could be performed. The
substitution of non-halogenated heterocyclic rings with serotonin-like indole moiety could
be performed to increase the SERT affinity. Like vilazodone, the two SERT-selective hits
could also be rationally optimized as multi-site drugs.
More specifically, SM-10 having the lowest affinity towards SERT has three
stereo centers present. The isolation and affinity measurement of different enantiomers of
SM-10 could also be performed to identify the higher affinity analogue. Moreover,
different combinations of halogen substitution on the phenyl ring could also be identified
for optimal SERT inhibition.
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Computationally, the hits identified showed an array of interactions with residues
in the S2 pocket. Mutagenesis studies on these residues could be carried out in an effort to
confirm that these ligands are indeed binding in the S2 pocket as predicted. Specifically,
the residues Arg104 (TM1), Tyr107 (TM1), Lys490 (TM10), and Glu493 (TM10) could
be mutated to alanine to disrupt the H-bonding potential. Likewise, the halogen binding
pocket residues Leu 99 (TM1), Trp103 (TM1) and Ile179 (TM3) could also be mutated to
ascertain the importance of this pocket.
Inhibitor binding pocket identification in MATs is a challenging task. The DAT
study developed and analyzed protein-ligand interaction fingerprints (PLIF) for three
structurally different photoprobes. Preliminary results suggest the role of Ser308, Asp312
and Asp475 residues forming a covalent bond with the photoprobes. Mutational studies of
these residues could be performed to ascertain the location of covalent bond formation.
Additionally, mass spectrometry studies could be performed to better corroborate with the
PLIF and mutational data.
The MEK5 kinase study led to the rational design of several series of inhibitors.
The MEK5 inhibitory cellular assay could be performed on the inhibitors to better
understand the mechanics of inhibition. Moreover, the biological results could help in the
validation and refinement of the MEK5 homology model. The biological activity of the
central ring modification series could provide minimal substitution required for MEK5
inhibition. In addition, this series will help in improving the solubility of these analogs by
eliminating the hydrophobic halogen groups on the rings.
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